<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Mol Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Cell Mol Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">2394</journal-id><journal-id journal-id-type="pmc-domain">cmi</journal-id><journal-title-group><journal-title>Cellular and Molecular Immunology</journal-title></journal-title-group><issn pub-type="ppub">1672-7681</issn><issn pub-type="epub">2042-0226</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10805787</article-id><article-id pub-id-type="pmcid-ver">PMC10805787.1</article-id><article-id pub-id-type="pmcaid">10805787</article-id><article-id pub-id-type="pmcaiid">10805787</article-id><article-id pub-id-type="pmid">38148330</article-id><article-id pub-id-type="doi">10.1038/s41423-023-01116-8</article-id><article-id pub-id-type="publisher-id">1116</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Cankat</surname><given-names initials="S">S.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-0030-2469</contrib-id><name name-style="western"><surname>Demael</surname><given-names initials="MU">M. U.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0537-6715</contrib-id><name name-style="western"><surname>Swadling</surname><given-names initials="L">L.</given-names></name><address><email>l.swadling@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1201</institution-id><institution>Division of Infection and Immunity, Institute of Immunity and Transplantation, </institution><institution>University College London, Pears Building, </institution></institution-wrap>London, NW3 2PP UK </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2024</year></pub-date><volume>21</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">454003</issue-id><fpage>103</fpage><lpage>118</lpage><history><date date-type="received"><day>1</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>25</day><month>01</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-21 23:25:34.860"><day>21</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41423_2023_Article_1116.pdf"/><abstract id="Abs1"><p id="Par1">Members of the <italic toggle="yes">coronaviridae</italic> family are endemic to human populations and have caused several epidemics and pandemics in recent history. In this review, we will discuss the feasibility of and progress toward the ultimate goal of creating a pan-coronavirus vaccine that can protect against infection and disease by all members of the coronavirus family. We will detail the unmet clinical need associated with the continued transmission of SARS-CoV-2, MERS-CoV and the four seasonal coronaviruses (HCoV-OC43, NL63, HKU1 and 229E) in humans and the potential for future zoonotic coronaviruses. We will highlight how first-generation SARS-CoV-2 vaccines and natural history studies have greatly increased our understanding of effective antiviral immunity to coronaviruses and have informed next-generation vaccine design. We will then consider the ideal properties of a pan-coronavirus vaccine and propose a blueprint for the type of immunity that may offer cross-protection. Finally, we will describe a subset of the diverse technologies and novel approaches being pursued with the goal of developing broadly or universally protective vaccines for coronaviruses.</p><p id="Par2">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d32e186" orientation="portrait" xlink:href="41423_2023_1116_Figa_HTML.jpg"/>
</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Vaccine</kwd><kwd>Coronavirus</kwd><kwd>Cross-reactive immunity</kwd><kwd>Cross-protection</kwd><kwd>Universal</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Vaccines</kwd><kwd>Viral infection</kwd><kwd>Cellular immunity</kwd><kwd>Humoral immunity</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000265</institution-id><institution>RCUK | Medical Research Council (MRC)</institution></institution-wrap></funding-source><award-id>MR/X502984/1</award-id><award-id>MR/W006774/1</award-id><principal-award-recipient><name name-style="western"><surname>Demael</surname><given-names>M. U.</given-names></name><name name-style="western"><surname>Swadling</surname><given-names>L.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000268</institution-id><institution>RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)</institution></institution-wrap></funding-source><award-id>BB/T008709/1</award-id><principal-award-recipient><name name-style="western"><surname>Cankat</surname><given-names>S.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; CSI and USTC 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">The COVID-19 pandemic has highlighted the significant effect that <italic toggle="yes">emerging viral infections can have on global health</italic>. Simultaneously, the pandemic has established the <italic toggle="yes">positive impact that effective vaccine strategies</italic> can have on mitigating the global burden of disease and highlighted the importance of understanding the <italic toggle="yes">immune mechanisms underpinning protective vaccines</italic>.</p><p id="Par4">In the three and a half years since the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ~770 million (M) infections and ~7&#8201;M related deaths have been reported [<xref ref-type="bibr" rid="CR1">1</xref>]; furthermore, these data are likely gross underestimates of the true global impact of the virus. The panel of 18 World Health Organization (WHO)-licensed vaccines changed the course of the pandemic, and these vaccines are estimated to have prevented between 14 and 20&#8201;M deaths in their first year alone [<xref ref-type="bibr" rid="CR2">2</xref>]. Despite the WHO declaring that COVID-19 was no longer a global emergency as of May 2023, there is still a significant unmet clinical need and global economic cost associated with currently circulating variants of SARS-CoV-2. Accordingly, there is a strong consensus in the scientific community regarding the need to develop more effective next-generation vaccines [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par5">The COVID-19 pandemic has also renewed interest in developing pan-family or universal vaccines&#8212;i.e., vaccines that could offer broad protection against all members of a viral family. The key rationale for a universal vaccine approach is the continued burden of disease associated with endemic human coronaviruses (HCoVs), the unpredictability of future SARS-CoV-2 variants, and the potential for zoonotic spill-over events. Since three of the major pandemics in the past two decades have been caused by coronaviruses, the demand for a proactive approach to coronavirus vaccines is especially warranted.</p><p id="Par6">In this review, we will first outline the <italic toggle="yes">need for a pan-coronavirus vaccine</italic> and then focus on knowledge derived from <italic toggle="yes">cross-reactive and heterosubtypic immunity</italic> in SARS-CoV-2 infection. We will discuss how this knowledge has shed more light on the feasibility of developing a pan-coronavirus vaccine. Finally, we will provide an update on current progress regarding the use of repurposed or novel approaches for <italic toggle="yes">next-generation coronavirus vaccines</italic>.</p></sec><sec id="Sec2"><title>What is a pan-coronavirus vaccine?</title><p id="Par7">A pan-coronavirus vaccine is a vaccine that is effective at preventing severe disease and/or infection caused by all viruses of the coronavirus family (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). In contrast, the current widely employed SARS-CoV-2 vaccines adopt a narrow-spectrum approach &#8211; they deliver spike (S) glycoproteins that vary antigenically between strains, resulting in immune protection that is predominantly species-specific or even variant-specific [<xref ref-type="bibr" rid="CR5">5</xref>].<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Phylogeny of coronaviruses and the breadth of protection afforded by different types of vaccines. Updated vaccines containing Omicron BA.1 or later sequences of spike have been designed to offer improved <italic toggle="yes">single-variant</italic> protection against currently circulating strains of SARS-CoV-2 compared with licensed vaccines. Next-generation vaccines are being designed to offer broader protection, for instance, <italic toggle="yes">pan-variant</italic> vaccines that could target all variants of the single viral species, SARS-CoV-2; <italic toggle="yes">pan-subgenus</italic> vaccines that target all members of the subgenus sarbecoviruses (including also SARS-CoV-1); <italic toggle="yes">pan-genus</italic> vaccines that include all members of the genus &#946;-coronavirus (further including MERS-CoV, HCoV HKU1 and OC43); <italic toggle="yes">pan-subfamily</italic> vaccines that target all Orthocoronavirinae (also including alpha-coronaviruses HCoV NL63 and 229E); and <italic toggle="yes">pan-coronavirus</italic> vaccines that target all species within the Coronaviridae family. Created with BioRender.com</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e274" position="float" orientation="portrait" xlink:href="41423_2023_1116_Fig1_HTML.jpg"/></fig></p><p id="Par8">An intermediate goal has been to develop vaccines against a subset of these viruses, referred to as <italic toggle="yes">broadly protective</italic> coronavirus vaccines rather than <italic toggle="yes">pan-</italic> or <italic toggle="yes">universal</italic> vaccines. The <italic toggle="yes">Coronaviridae</italic> family of positive-stranded RNA viruses contains three subfamilies, including the <italic toggle="yes">Orthocoronavirinae</italic> subfamily, to which SARS-CoV-2 belongs. The <italic toggle="yes">Orthocoronavirinae</italic> subfamily is further divided into four genera (<italic toggle="yes">&#945;</italic>, &#946;, <italic toggle="yes">&#947;</italic>, &#948;; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Several pan-coronavirus approaches are in development, which will be discussed in detail below. These approaches include either targeting all <italic toggle="yes">&#946;</italic>-coronaviruses, targeting a subset of these viruses (such as sarbecoviruses), or even targeting a single <italic toggle="yes">species</italic> with the aim of developing a pan-variant or &#8220;variant-proof&#8221; vaccine for SARS-CoV-2 (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Key characteristics of an ideal pan-coronavirus vaccine and the relative performance of current best-licensed vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">Ideal pan-coronavirus vaccine</th><th colspan="1" rowspan="1">Current best in class licensed vaccine (example mRNA or Ad spike)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Breadth</td><td colspan="1" rowspan="1">All coronavirus family including all current HCoV, SARS-CoV-2 (all variants) and emerging animal coronaviruses</td><td colspan="1" rowspan="1">Largely strain/variant specific</td></tr><tr><td colspan="1" rowspan="1">Protection conferred</td><td colspan="1" rowspan="1">Protection from infection, transmission, and disease</td><td colspan="1" rowspan="1">Protection from severe disease, limited protection from infection</td></tr><tr><td colspan="1" rowspan="1">Durability</td><td colspan="1" rowspan="1">Sustained protection from a single dose</td><td colspan="1" rowspan="1">Requires boosters every 6&#8211;12 months</td></tr><tr><td colspan="1" rowspan="1">Safety Profile</td><td colspan="1" rowspan="1">Mild reactogenicity, no severe adverse events</td><td colspan="1" rowspan="1">Mild-moderate reactogenicity (mRNA&gt;Ad), rare severe events (e.g., thrombosis with thrombocytopenia syndrome)</td></tr><tr><td colspan="1" rowspan="1">Patient Population</td><td colspan="1" rowspan="1">Universal (including immunocompromised)</td><td colspan="1" rowspan="1">Potentially universal, boosting now in clinically vunerable only</td></tr><tr><td colspan="1" rowspan="1">Route of Administration</td><td colspan="1" rowspan="1">Needle free, mucosal targeting?</td><td colspan="1" rowspan="1">Intradermal</td></tr><tr><td colspan="1" rowspan="1">Manufacturing</td><td colspan="1" rowspan="1">Scalable&#160;for global roll-out</td><td colspan="1" rowspan="1">Scalable for global roll-out</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">Room temperature</td><td colspan="1" rowspan="1">Adenovirus 2&#8211;8&#8217;C 1 year [<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td colspan="1" rowspan="1">Cost per dose</td><td colspan="1" rowspan="1">Inexpensive and not-for-profit</td><td colspan="1" rowspan="1">Adenovirus $2&#8211;5, mRNA $10&#8211;25 [<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr></tbody></table></table-wrap></p><sec id="Sec3"><title>Why is there a clinical need for a pan-coronavirus vaccine?</title><p id="Par9">There are six coronaviruses that continue to cause disease in humans: SARS-CoV-2, Middle Eastern respiratory syndrome coronavirus [MERS-CoV], and the four seasonal endemic HCoVs (OC43, HKU1, 229E, and NL63). Prophylactic vaccines would be beneficial in reducing the morbidity caused by&#160;these viruses. The clinical spectrum of disease caused by these virus ranges from asymptomatic infection to severe disease, characterized by pneumonia, dyspnea, and febrile illness, progressing in severe cases into acute respiratory distress, sepsis, and death from multiple organ failure [<xref ref-type="bibr" rid="CR6">6</xref>]. The requirement for hospitalization and mechanical ventilation in patients with severe COVID-19 (mostly in high-risk groups, such as elderly individuals or those with comorbidities) caused acute strains on healthcare systems at the peak of the pandemic, thus leading to national lockdowns and vaccination programs.</p><p id="Par10">The chronic morbidity burden of COVID-19 extends much wider, with up to 10% of individuals across a spectrum of initial disease severity estimated to suffer from long COVID, a durable multisystemic condition with multiple adverse outcomes, such as, myalgia, fatigue, and neurocognitive dysfunction [<xref ref-type="bibr" rid="CR7">7</xref>]. <italic toggle="yes">The underlying mechanisms and the immunopathology of long COVID-19 are a continued area of intense investigation</italic> [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par11">Four seasonal human coronaviruses were circulating widely prior to the COVID-19 pandemic, accounting for ~10&#8211;30% of upper respiratory tract infections [<xref ref-type="bibr" rid="CR10">10</xref>]. However, these seasonal coronaviruses typically cause self-limited infection and asymptomatic or mildly symptomatic disease. As a result, vaccine development was deemed to be a low priority, and it was thought that due to concurrent circulation, a quadrivalent vaccine would be needed. There is, however, renewed interest in HCoV-targeting vaccines. Moderna has developed an mRNA vaccine, mRNA-1287, to target the four seasonal HCoVs. Although no coronavirus vaccines had obtained regulatory approval prior to the SARS-CoV-2 pandemic, a vaccine protecting against seasonal coronaviruses could have enormous economic and health benefits globally [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par12">MERS-CoV persists in dromedary camels in Middle Eastern countries, causing sporadic outbreaks in humans with limited human-to-human transmission. However, MERS-CoV has a case fatality rate of ~33% across 2500 cases [<xref ref-type="bibr" rid="CR12">12</xref>]; thus, there is continued interest in a prophylactic vaccine [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par13">Vaccines continue to be our best tool to limit the impact of SARS-CoV-2. For example, there remain &gt;17.5&#8201;M at-risk individuals and their contacts (&gt;65&#8201;yrs old, care home residents, clinical risk groups and their carers/household contacts, frontline health workers, and social care workers) who received booster vaccinations prior to the winter of 2022 in the UK, and a similar number of individuals were offered boosters in 2023 [<xref ref-type="bibr" rid="CR14">14</xref>]. A pan-coronavirus vaccine would have wide-ranging impact by addressing an important unmet clinical need for endemic and epidemic coronaviruses.</p></sec><sec id="Sec4"><title>Could vaccines be designed to target emerging coronaviruses?</title><p id="Par14">The urgent need for a pan-coronavirus vaccine, as opposed to a narrow-range SARS-CoV-2 vaccine, is underscored by the high probability of the continued emergence of coronaviruses with pathogenic potential [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par15">The ability of viral variants to evade immunity was brought to the center stage by the emergence of the Omicron strain of SARS-CoV-2, which was first reported in November 2021; this variant harbored &gt;30 amino acid substitutions within spike, thereby producing conformational changes that resulted in the evasion of recognition by neutralizing antibodies [<xref ref-type="bibr" rid="CR16">16</xref>]. Subsequently, several reports confirmed that vaccines containing ancestral Wuhan-Hu-1 spike sequences only conferred limited protection against infection by Omicron [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], which soon became one of the dominant global strains.</p><p id="Par16">The emergence of viruses with novel immunogenic properties is neither surprising nor unexpected; rather, it reflects the <italic toggle="yes">modus operandi</italic> of viruses, which are sustained by cycles of diversification and adaptation.</p><p id="Par17">At the molecular level, SARS-CoV-2, similar to other RNA viruses, uses an intrinsically imprecise RNA-dependent RNA polymerase, resulting in very high mutation rates [<xref ref-type="bibr" rid="CR18">18</xref>]. At the ecological level, coronaviruses have broad host tropism across birds and mammals, with evidence of extensive transmission between species. Numerous bat species transmit sarbecoviruses to one another and to numerous mammals, including humans; among the nine coronaviruses known to infect humans, five are most likely to have originated from bats [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Mixed infection within a single host opens the window for further diversification by genetic recombination.</p><p id="Par18">Zoonotic events are probably highly underestimated due to poor surveillance [<xref ref-type="bibr" rid="CR20">20</xref>]. For instance, MERS-CoV first caused an epidemic in humans after zoonotic transmission in 2012, although serological evidence suggests that it had been circulating in dromedary camels since the 1980s. Multiple separate cases of cattle coronaviruses being transmitted to humans have been described [<xref ref-type="bibr" rid="CR21">21</xref>], and viruses related to feline and canine coronaviruses have been isolated from patients with respiratory symptoms [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. A porcine &#948;-coronavirus was isolated from three Haitian children with acute undifferentiated fever, which was the first occurrence of a &#948;-coronavirus in humans [<xref ref-type="bibr" rid="CR24">24</xref>]. Surveillance of wild animals has also revealed high seropositivity rates against SARS-CoV-2 in white-tailed deer in the United States [<xref ref-type="bibr" rid="CR25">25</xref>]. Anthroponosis (human to animal transmission) and reverse anthroponosis (spill-over back into humans after a period of adaptation in the new animal reservoir) have been detected for SARS-CoV-2, thus impeding the eradication of SARS-CoV-2 and increasing the risks of recombination, evolution and immune evasion [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par19">We currently have little understanding of the universe of potentially endemic coronaviruses circulating in animal hosts, although a combination of high mutagenic properties and broad host range means that there is a persistent threat of novel zoonotic emergence. Furthermore, SARS-CoV-2 diversification is ongoing within human populations.</p><p id="Par20">Due to the wide-ranging impact of the COVID-19 pandemic, there has been a renewed interest in <italic toggle="yes">proactive vaccinology</italic>, in which research efforts are concentrated on designing vaccines that can induce immunity that would cross-protect against future zoonosis. A pan-coronavirus vaccine could therefore represent the first in a line of &#8220;proactive vaccines&#8221; that could be ready for rapid testing during emerging outbreaks.</p><p id="Par21">A pan-coronavirus vaccine approach could mitigate the substantial costs associated with repeated development and distribution of potentially ineffective vaccines in the face of an ever-changing viral landscape. A pan-coronavirus vaccine thus represents an <italic toggle="yes">ultimate goal</italic>. Below, we will discuss how the study of SARS-CoV-2 has reignited interest in a pan-coronavirus vaccine, what this vaccine might look like, and some of the approaches being pursued.</p></sec></sec><sec id="Sec5"><title>What have we learned from first-generation vaccines?</title><sec id="Sec6"><title>Against the emerging virus</title><p id="Par22">Several complete SARS-CoV-2 viral genomes were available at the beginning of 2020 [<xref ref-type="bibr" rid="CR26">26</xref>], and early analysis suggested very little sequence diversity [<xref ref-type="bibr" rid="CR15">15</xref>]. This informed the rapid development of vaccines even before the pandemic potential of SARS-CoV-2 was predicted by many. The front-runners were vaccines that were based around these ancestral sequences and included only the surface glycoprotein spike.</p><p id="Par23">With just a few exceptions, licensed vaccines for viruses are designed to <italic toggle="yes">induce neutralizing antibodies (nAbs)</italic>, which can bind to extracellular viruses and inhibit viral entry and infection. The spike protein was therefore selected because it is an abundant surface protein of the virion and the main target for nAb against the related SARS-CoV-1 [<xref ref-type="bibr" rid="CR27">27</xref>]. All first-generation vaccines also induce modest CD4 and CD8 T-cell responses due to the large number of T-cell epitopes within the spike protein and within other structural antigens included in vaccines based on inactive forms of the virus. Two widely employed vaccines used mRNA platforms to deliver spike (Spikevax-mRNA-1273, Moderna; and Comirnaty-BNT162b2, Pfizer-BioNTech), and three vaccines used nonreplicative adenoviral vectors (Vaxzevria/Covishield/AZD1222/ChAdOx1-spike, AstraZeneca/Serum Institute of India; Ad26.COV.2, Johnson &amp; Johnson/Janssen; and Ad5-nCoV, Cansino Biologics; reviewed in [<xref ref-type="bibr" rid="CR28">28</xref>]). Later additions to the global vaccine repertoire included whole inactivated viruses (CoronaVac, Sinovac; Covilo/BBIBP-CorV, Sinopharm; and Covaxin/BBV512, Bharat Biotech) and subunit proteins (Covovax, Serum Institute of India; and NVXCoV2373, Novavax), which were also based around ancestral sequences.</p><p id="Par24">Widespread rollout and unprecedented research interest have offered ample opportunity for studies into the optimal <italic toggle="yes">vaccine regimen</italic> for protection. Notable findings from these studies include the qualitative differences in immune response induced by different platforms (e.g., Ad vs. mRNA vs. inactive virus) or different heterologous prime-boost regimens; the effects of vaccine doses and the timing of boosters; and the effects of sex and age on vaccine efficacy (reviewed elsewhere [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]). This knowledge will be informative for the design of vaccines against other infectious agents.</p><p id="Par25">Vaccine efficacy studies determine how protective vaccine regimens are in a given cohort <italic toggle="yes">using defined end points</italic>, e.g., efficacy against symptomatic infection or against admission to intensive care. Protection against infection is the ultimate goal of vaccines, thus preventing the disease among individuals and breaking the chain of onward transmission. Many vaccines do not reach this high-bar, but they can still limit the severity of disease in those who become infected, thus protecting against hospitalization or death. A common way to measure vaccine efficacy is to test only symptomatic individuals during a trial rather than testing everyone weekly by PCR. This strategy could not be used to determine the efficacy of vaccines against asymptomatic infection. However, it would be easier to identify and record the number of hospitalizations, intensive care unit visits, and fatalities during vaccine trials when compared to infections, thus making it more feasible to assess the efficacy of a vaccine against severe disease. It can be difficult to generalize results across diverse populations; however, the wealth of data for SARS-CoV-2 vaccines has allowed systematic reviews and meta-analyses to integrate data from millions of vaccinations, thus resulting in some consistent rules about where vaccines have been effective [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par26">The high rates of infection globally have enabled the rapid determination of vaccine efficacy in several countries, reassuringly showing that several approaches have been highly protective against symptomatic infection [<xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>]. A recent meta-analysis of 29 trials highlighted the impressive efficacy of first-generation vaccines, showing that the combined <italic toggle="yes">efficacy of a full course of vaccination against hospitalization was greater than 95%</italic> [<xref ref-type="bibr" rid="CR5">5</xref>]. Yang et al. found that efficacy was consistent across mRNA, DNA, viral vectors, and inactive viruses and that differences in trial design, population characteristics and other factors were stronger contributors to heterogeneity than vaccine modality. Collectively, this body of evidence will be useful to build on for next-generation vaccine development.</p></sec><sec id="Sec7"><title>Need for better SARS-CoV-2 vaccines</title><p id="Par27">There are several limitations to the current licensed vaccines that we will consider below. Ongoing waves of SARS-CoV-2 infection sustain the scenario where in the absence of improved vaccines or immunotherapies, clinically vulnerable individuals will still require annual or biannual vaccinations with updated immunogens matched to circulating variants.</p><sec id="Sec8"><title>Limited ability to block infections</title><p id="Par28">What has become clear is that first-generation vaccines are somewhat limited in their ability to prevent infections, with an efficacy of ~75% for preventing symptomatic infections but only ~45% for preventing asymptomatic infections [<xref ref-type="bibr" rid="CR5">5</xref>]. This is particularly the case for the sublineages of the Omicron variant, due to its ability to evade antibodies from prior exposure to both earlier variants and vaccines [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. As a result, widespread breakthrough infections occur even in populations with near-universal vaccine coverage.</p></sec><sec id="Sec9"><title>Nonresponders</title><p id="Par29">For all current vaccines, there is a significant population of individuals who are considered nonresponders (i.e., nonseroconverters), particularly those with an inability to mount effective B-cell responses. These nonseroconverters include people on B-cell-depleting therapy or people with inborn errors of immunity, as these individuals are typically more susceptible to prolonged infection and higher rates of progression to severe disease [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Despite low fatality rates globally, high rates of infection pose a persistent challenge to shield vulnerable individuals who cannot be productively vaccinated.</p></sec><sec id="Sec10"><title>Durability</title><p id="Par30">Efficacy against symptomatic infection also waned over time for all vaccines (average decrease of 13.6% per month, 95% CI 5.5&#8211;22.3 [<xref ref-type="bibr" rid="CR5">5</xref>]; a decrease from 83% to ~22% from 1 to 5 months post vaccination across 18 studies [<xref ref-type="bibr" rid="CR30">30</xref>]). However, efficacy against severe disease does appear more durable, with vaccines leading to a ~90% reduction in severe disease at 5 months postvaccination [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. This waning of efficacy is also observed for booster vaccination when Omicron is the dominant circulating variant, with Menegale et al. reporting only a 30% vaccine efficacy against symptomatic infection at 9 months after a booster [<xref ref-type="bibr" rid="CR38">38</xref>]. The challenges associated with sustained vaccine efficacy include the waning of antibody responses as well as neutralization evasion [<xref ref-type="bibr" rid="CR39">39</xref>&#8211;<xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec11"><title>Mucosal immunity</title><p id="Par31">Currently licensed SARS-CoV-2 vaccines are all delivered parenterally via intramuscular injection, which leads to some limitations for vaccine roll-out and potentially for protective efficacy (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Needle use can reduce uptake due to the fear of needles, it can lead to needle-stick injuries; furthermore, when blood hygiene guidance is not followed and needles are reused, the spread of blood-borne infections can occur [<xref ref-type="bibr" rid="CR42">42</xref>]. Alternative methods of administering vaccines, such as oral, sublingual, intranasal, and aerosol administration, could address these limitations.</p><p id="Par32">The route of administration can have a profound impact on the localization of the immunity generated [<xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref>]. Alternative routes of administration are being investigated in the context of coronavirus vaccines with the aim of <italic toggle="yes">inducing strong mucosal immunity at the site of viral infection and replication</italic> to improve vaccine efficacy. Vaccine-induced respiratory mucosal immunity is vital for protection against SARS-CoV-1 in animal models [<xref ref-type="bibr" rid="CR46">46</xref>], and greater numbers of total tissue-resident T cells in the lungs have been associated with protection from severe COVID-19 [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. In particular, it may be essential to have preexisting immune memory at the sire of viral exposure in the airways to block infection.</p><p id="Par33">Currently licensed vaccines are not targeted to the airways, and thus, they induce limited mucosal immunity. However, SARS-CoV-2-reactive immunity can be detected in the airways after previous infection [<xref ref-type="bibr" rid="CR49">49</xref>] or as preexisting cross-reactive immunity [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Next-generation mucosally targeted vaccines may be able to draw T and B cells from the blood and lymphatics into the mucosa, prime de novo responses locally, or even boost immunity generated by previous infections of the airways. It has previously been suggested that mucosal immunity tends to be short-lived and that vaccines targeted to the mucosa may be less immunogenic at these sites [<xref ref-type="bibr" rid="CR43">43</xref>], which are limitations that need to be overcome for efficacious mucosal-targeted vaccines.</p></sec><sec id="Sec12"><title>Cross-reactive immunity</title><p id="Par34">Licensed vaccines were originally designed to target the SARS-CoV-2 Wuhan-Hu-1 strain without knowledge of&#160;how global transmission and preexisting cross-reactive infection or vaccine-induced immunity would influence viral sequence evolution. <italic toggle="yes">We are now in a better position to design vaccines to induce immunity that can cross-recognize current variants and other human and animal coronaviruses</italic>.</p><p id="Par35">Both Pfizer and Moderna have developed bivalent vaccines containing ancestral SARS-CoV-2 and an Omicron variant. These bivalent vaccines can induce stronger nAb titers to Omicron than first-generation vaccines [<xref ref-type="bibr" rid="CR52">52</xref>&#8211;<xref ref-type="bibr" rid="CR54">54</xref>]. Previous infection with Wuhan-Hu-1 has been associated with a weaker induction of Omicron-specific nAbs [<xref ref-type="bibr" rid="CR55">55</xref>], suggesting an imprinting effect. Each antigen exposure via infection or vaccination reshapes immune memory and its potential to protect against future homologous or heterologous variants. It will be important to determine <italic toggle="yes">how previous infection and vaccination affect the immune response to next-generation vaccines</italic>. For instance, it has been suggested that Omicron bivalent vaccines predominantly recall B cells targeting ancestral SARS-CoV-2 epitopes rather than inducing de novo Omicron responses.</p><p id="Par36">Mutations in Omicron may have led to a loss of B-cell epitopes, but this does not imply that novel Omicron-specific epitopes were exposed as a result, thus stressing the need for further investigation into the extent to which Omicron-specific immunity is achievable.</p></sec></sec></sec><sec id="Sec13"><title>What would an ideal pan-coronavirus vaccine look like?</title><p id="Par37">The impact of vaccines can be considered on an individual or population level and offer different types of protection. For instance, on a personal level, the ideal vaccine will offer immunity that is sterilizing so that infection never establishes in a host. On the population level, an ideal vaccine would limit transmission. However, vaccines that limit disease still have benefits, as they prevent infections from causing severe disease and death.</p><p id="Par38">If we were to design vaccines under the assumption that producing the gold-standard pan-coronavirus vaccine is achievable, we would aim to induce immunity that recognizes the <italic toggle="yes">breadth of diversity across the Coronaviridae family</italic>. Vaccines should also be designed to overcome the limitations of the current SARS-CoV-2 vaccines named above: they should <italic toggle="yes">prevent infection, viral shedding, onward transmission, and disease; they should be effective in all age groups and in pregnant women; and they should offer durable protection, potentially lifelong, after one or a limited number of doses</italic> (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Other vaccine characteristics that impact the manufacture and roll-out of the vaccine also deserve consideration (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><sec id="Sec14"><title>What type of immune memory do we need to induce for an effective coronavirus vaccine?</title><p id="Par39">Current approaches to vaccinology largely rely on trial and error, with immunogenic vaccines progressing to increasingly large human trials to determine their efficacy. A more efficient approach would be to identify precise <italic toggle="yes">correlates of protection</italic> that can be used to inform vaccine design and to benchmark vaccines. Correlates of protection can be identified by studying immunity in protected and unprotected individuals during natural infection studies but can also be inferred from postvaccination protection. Due to the complex interaction of different factors that contribute to an effective immune response, there may be more than one correlate of protection, and the mechanisms of protection during natural infection may differ from those seen after vaccination.</p><p id="Par40">The wealth of data regarding the efficacy and immunogenicity of first-generation SARS-CoV-2 vaccines can support informed conclusions about the likely immune mechanisms of protection. Yang et al. found that higher <italic toggle="yes">nAb, anti-RBD (receptor binding domain) antibodies and anti-spike antibodies were associated with higher efficacy</italic> against infection and severe disease; however, there was no clear linear correlation, as a <italic toggle="yes">large proportion of the heterogeneity in efficacy was not explained by antibodies</italic> [<xref ref-type="bibr" rid="CR5">5</xref>]. This is consistent with many animal studies and in-depth immunological studies that show, as expected, a measurable contribution to protection via non-nAb [<xref ref-type="bibr" rid="CR56">56</xref>&#8211;<xref ref-type="bibr" rid="CR58">58</xref>], NK cells [<xref ref-type="bibr" rid="CR59">59</xref>], and MAIT cells [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>] and in particular T cells [<xref ref-type="bibr" rid="CR62">62</xref>&#8211;<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par41">Prior to the roll-out of vaccines, the expansion of SARS-CoV-2-specific T cells and an interferon response were detectable in the blood even in the week preceding PCR positivity in asymptomatic and mild cases of primary SARS-CoV-2 infection [<xref ref-type="bibr" rid="CR66">66</xref>]. In contrast, antibodies were detectable in the blood two weeks post-PCR positivity. During breakthrough infection after vaccination, T-cell and plasmablast activation occur rapidly, while nAb and memory B-cell activation occurs ~2 weeks postinfection. This pattern suggests the important role of early recall responses of T cells and non-nAbs in protection from severe disease [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. <italic toggle="yes">Therefore, T-cell responses appear to be important not only in the clearance of virus and limiting disease but also in the early control of viral replication</italic> [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par42">It remains important that correlative and mechanistic studies continue to unpick the complex immune response to coronaviruses to hone-in on which aspects of immunity are most effective against coronaviruses to inform vaccine design.</p></sec><sec id="Sec15"><title>Does pan-coronavirus immunity exist?</title><p id="Par43">Despite a lack of precise correlates of protection, it is clear that a pan-coronavirus vaccine will need to induce immunity that <italic toggle="yes">cross-recognizes the full range of diversity</italic> across this viral family. <italic toggle="yes">What evidence is there that such immunity exists?</italic></p><p id="Par44">RNA viruses have some of the highest mutation rates due to their use of RNA-dependent RNA polymerase rather than host proofreading machinery [<xref ref-type="bibr" rid="CR18">18</xref>]. Genomic sections displaying sequence conservation over time within a single viral species or evolutionary conservation between members of the coronavirus family despite high mutation rates are indicative of <italic toggle="yes">essential regions</italic> of the viral genome that are functionally constrained, such as the fusion peptide within the spike S2 region [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Therefore, a pan-coronavirus vaccine that is able to induce immunity targeting combinations of epitopes conserved across the whole coronavirus family should also protect against future variants and emerging viral species, in which these epitopes will likely be retained owing to functional constraints.</p><sec id="Sec16"><title>Cross-reactive antibodies</title><p id="Par45">The Omicron variant has exemplified the difficulty of inducing cross-protective antibodies even within a single coronavirus species. What differentiated Omicron from previous SARS-CoV-2 variants was its emergence with a large panel of amino acid substitutions in the spike S1 region, which led to a loss of recognition by the RBD binding nAb. Importantly, these mutations also led to the loss of recognition by a wide panel of monoclonal antibodies undergoing testing in the clinic [<xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par46">Due to ubiquitous exposure, most adults are seropositive to all four seasonal coronaviruses; however, it was shown early in the pandemic that this exposure did not lead to preexisting antibodies that could cross-recognize SARS-CoV-2 in most individuals [<xref ref-type="bibr" rid="CR71">71</xref>]. In the few individuals who did have preexisting cross-reactive antibodies, these often targeted the S2 region of spike that is more conserved across coronaviruses but that predominantly induces nonneutralizing antibodies [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Interestingly, monoclonal antibodies that target the conserved fusion peptide within S2 and display a broad reactivity profile across all SARS-CoV-2 variants and animal coronaviruses have been identified [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR74">74</xref>&#8211;<xref ref-type="bibr" rid="CR76">76</xref>]. RBD-targeting nAbs that recognize Omicron and a range of &#946;-coronaviruses have also been identified, thus indicating key conserved RBD sites toward which vaccines can be designed [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par47">Similar to the case of broadly nAb to HIV, the description of rare subset of broadly targeting antibodies is not sufficient to elucidate the mechanism by which we can elicit these antibodies in a wide range of individuals by vaccination. However, it does serve as a proof-of-concept that broadly targeting immunity exists, thus suggesting potential routes of induction, which can be experimentally tested.</p><p id="Par48">A particular challenge for pan-coronavirus vaccines is the diverse use of entry receptors by different coronaviruses (e.g., <italic toggle="yes">ACE2</italic>: SARS-CoV-1, SARS-CoV-2, NL63; <italic toggle="yes">DDP4</italic>: MERS; <italic toggle="yes">9-O-acetylated sialic acid</italic>: OC43, HKU1; <italic toggle="yes">aminopeptidase N receptor</italic>: 229E). Neutralizing antibodies often rely on physically inhibiting the interaction between the virus receptor binding domain and the host entry receptor; therefore, pan-coronavirus vaccines would need to target epitopes that can inhibit binding to all coronavirus entry receptors.</p><p id="Par49">Although they are understudied, a longitudinal analysis of HCoV-OC43 and 229E suggested that they constantly adapt to avoid host immunity [<xref ref-type="bibr" rid="CR79">79</xref>]; in particular, these viruses acquire mutations in S1 that lead to a ladder-like phylogenetic tree. In another study, historic sera, which were able to neutralize 229E sequences from the time of collection, failed to neutralize strains isolated 8&#8211;17 years later; furthermore, modern sera from children were more effective at neutralizing contemporary virus, thus demonstrating the difficulty of designing a vaccine against a moving target [<xref ref-type="bibr" rid="CR80">80</xref>].</p><p id="Par50">Recent analysis shows that the antibodies induced in the small population of SARS-CoV-1-exposed individuals who were subsequently exposed to SARS-CoV-2 appear to be particularly broadly cross-reactive, suggesting that exposure to related coronavirus species can select for cross-reactive antibodies [<xref ref-type="bibr" rid="CR81">81</xref>]. This evidence lends support to the fact that mosaic antigens and/or sequential boosting of antibodies may be needed to selectively expand cross-reactive immunity.</p></sec><sec id="Sec17"><title>Cross-reactive T cells</title><p id="Par51">T cells are inherently more cross-reactive than B cells because they recognize short peptide sequences presented on the major histocompatibility complex (MHC) rather than complex structural epitopes and because they can target conserved internal proteins rather than just surface and structural proteins that are accessible to antibodies on extracellular virus. Additionally, the interaction between T cells and MHC-peptide is highly flexible, thus enabling a single T-cell receptor sequence to recognized in the region of 1&#8201;&#215;&#8201;10<sup>6</sup> different MHC-peptide targets [<xref ref-type="bibr" rid="CR82">82</xref>].</p><p id="Par52">Most SARS-CoV-2-specific T cells have been shown to be at least panvariant reactive, with epitopes being retained in currently circulating viruses [<xref ref-type="bibr" rid="CR83">83</xref>&#8211;<xref ref-type="bibr" rid="CR85">85</xref>]; thus, aside from a few key exceptions, T-cell escape is rare [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. Antibody escape by Omicron has led to a marked drop in vaccine efficacy against infection; however, robust protection against severe disease has been maintained. In the context of low or often undetectable neutralizing activity of antibodies, the fact that vaccine- or previous SARS-CoV-2-induced immunity can retain its ability to limit viral replication and to clear infection indicates the important protective roles of non-nAbs and T cells.</p><p id="Par53">Cross-viral species recognition by coronavirus-reactive T cells has been well described, with SARS-CoV-2-reactive T cells being reported in samples taken before SARS-CoV-2 circulated in humans. <italic toggle="yes">Preexisting SARS-CoV-2 cross-reactive</italic> T cells have been widely identified and are detected in up to three-quarters of individuals using sensitive assays and in vitro expansion [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR88">88</xref>&#8211;<xref ref-type="bibr" rid="CR91">91</xref>]. Importantly, preexisting T cells have been shown to not only be cross-reactive to SARS-CoV-2 sequence peptides in vitro but also respond in vivo and have been associated with early control of viral infection, limited disease and stronger responses to vaccination [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. Many of these preexisting T cells target conserved epitopes within human coronaviruses, suggesting that they were induced by previous seasonal HCoV infection [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]; however, there are other minor sources of these cross-reactive T cells [<xref ref-type="bibr" rid="CR95">95</xref>&#8211;<xref ref-type="bibr" rid="CR98">98</xref>].</p><p id="Par54">Analyses of sequence evolution across the coronavirus family through evolutionary timescales and throughout the pandemic can help to <italic toggle="yes">identify regions that are conserved and, if immunogenic, amenable to eliciting broadly reactive immunity</italic>, especially in the context of selection pressure from increasing levels of vaccine-induced and infection-induced immunity.</p><p id="Par55">Although enriched in proteins with higher levels of total conservation, there are examples of conserved immunogenic epitopes in most, if not all, viral proteins [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. The RNA-dependent RNA polymerase (NSP12) and helicase (NSP13) of the replication-transcription complex (RTC) are the most conserved proteins when considering the rate of change at each amino acid site (homologies or nucleic acid diversity) over the course of the SARS-CoV-2 pandemic or conservation in sequence across HCoVs and the coronavirus family [<xref ref-type="bibr" rid="CR62">62</xref>]. This is expected due to their essential roles in the viral reproduction cycle. However, T-cell responses to conserved nonstructural regions &#8211; especially the RTC&#8212;are subdominant in detectable seropositive infections [<xref ref-type="bibr" rid="CR62">62</xref>]. This may be due to the low level of expression of these proteins, which are not encoded by subgenomic RNAs or present within the virion. Therefore, they are not needed in large quantities. <italic toggle="yes">Overcoming low protein abundance may offer an opportunity for vaccine-induced immunity to improve the responses seen in natural infection</italic>.</p></sec></sec><sec id="Sec18"><title>Could vaccine-induced T cells offer protection against infection?</title><p id="Par56">An ideal pan-coronavirus vaccine will limit infection and onward transmission rather than just prevent disease upon infection. However, is there evidence that <italic toggle="yes">infection-blocking immunity exists against SARS-CoV-2 and other coronaviruses?</italic></p><p id="Par57">An intensive study of health care workers (HCWs) in London from the week of the first UK lockdown showed that despite a high rate of exposure and infection relative to the general public [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR102">102</xref>], the majority of individuals remained seronegative and repeatedly tested negative on PCR. This seronegativity could reflect a lack of exposure to the virus or could indicate early control of the virus upon exposure and abortive infections [<xref ref-type="bibr" rid="CR67">67</xref>]. Abortive infections have been identified in seronegative individuals, a status&#160;confirmed with multiple spike and nucleoprotein sero-assays as well as pseudovirus neutralization. Abortive infections were detected by the coordinated expansion of SARS-CoV-2-specific T cells as well as the upregulation of a biomarker of infection&#8212;i.e., the interferon-stimulated gene IFI27&#8212;during the first pandemic wave of infections [<xref ref-type="bibr" rid="CR62">62</xref>].</p><p id="Par58">Abortive infection is a desirable outcome, as it precludes disease development and has a low risk of onward transmission due to viral replication levels being below the PCR detection threshold; furthermore, abortive infection serves as an important setting in which to study protective immunity [<xref ref-type="bibr" rid="CR67">67</xref>]. What was striking about the T-cell response in the HCWs with abortive infection was the <italic toggle="yes">enrichment for T cells targeting the conserved nonstructural proteins of open reading frame 1ab (ORF1ab), which make up the core of the RTC</italic> [<xref ref-type="bibr" rid="CR67">67</xref>]. An enrichment of RTC-specific T cells <italic toggle="yes">was observed at recruitment</italic> (prior to exposure) among individuals who went on to have an abortive infection relative to those who had a detectable infection. This finding suggests the direct role of RTC-specific T cells in protecting individuals from detectable infection upon exposure; therefore, <italic toggle="yes">RTC-specific T cells were identified as a correlate of protection from detectable infection</italic> [<xref ref-type="bibr" rid="CR67">67</xref>]. In support of the idea that cross-protective immunity exists, recent HCoV infections were found to be associated with less severe COVID-19 upon infection with ancestral SARS-CoV-2 [<xref ref-type="bibr" rid="CR103">103</xref>], and infection with SARS-CoV-2 of any variant was also associated with a reduced incidence of subsequent HCoV infection. In both cases, <italic toggle="yes">cross-protection was correlated with stronger T-cell responses</italic>, particularly NSP12/13 targeting CD8&#8201;+&#8201;T cells [<xref ref-type="bibr" rid="CR104">104</xref>].</p><p id="Par59">Preexisting cross-reactive T cells could contribute to rapid viral control due to the following characteristics: their <italic toggle="yes">adapted phenotype</italic>, as they are already differentiated to memory T cells poised to respond with rapid proliferation and immediate effector function; their <italic toggle="yes">location</italic>, as they are enriched at the site of viral exposure [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]; and their <italic toggle="yes">frequency</italic>, as they are already pre-expanded to higher magnitudes than in na&#239;ve individuals. For many studies, it was not possible to sample adaptive immunity pre-exposure; therefore, a combination of de novo and preexisting T-cell responses was studied and correlated with early control [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR105">105</xref>], often noting an enrichment for responses to conserved epitopes postexposure [<xref ref-type="bibr" rid="CR106">106</xref>].</p><p id="Par60">Overall, there is evidence that <italic toggle="yes">T cells are important in early viral control and infection blockade</italic>, thus providing support for the inclusion of T-cell antigens within next-generation vaccines alongside B-cell antigens.</p></sec></sec><sec id="Sec19"><title>What can we learn from universal vaccines against other viruses?</title><p id="Par61">The development of broadly protective vaccines has been attempted previously, particularly for influenza and Henipavirus. Below, we will briefly discuss what can be learned from this body of literature when designing pan-coronavirus vaccines.</p><p id="Par62">Henipavirus is a genus of negative-strand RNA viruses of the Paramyxoviridae family with a broad host range, primarily small mammals. These viruses have recently emerged as zoonotic infections. Hendra virus (HeV) is a bat-borne virus that causes deadly infections in both humans and animals, predominantly horses, with the flying fox identified as a key reservoir species [<xref ref-type="bibr" rid="CR107">107</xref>]. Nipah virus is another zoonotic Henipavirus that was identified during an outbreak in 1998 that caused ~265 infections and &gt;100 deaths in Malaysian pig farms [<xref ref-type="bibr" rid="CR108">108</xref>].</p><p id="Par63">Support for cross-protective immunity against HeV and Nipah virus comes from human and animal serology, which show cross-neutralization [<xref ref-type="bibr" rid="CR109">109</xref>]. A HeV vaccine that was developed and licensed for horses is the first vaccine against a containment category four human pathogen; this vaccine aims to limit bat-to-horse spread, as viral amplification in horses appears to be the main source of human infections [<xref ref-type="bibr" rid="CR110">110</xref>]. This subunit vaccine is based on the highly conserved G protein of HeV, which may explain cross-protection against Nipah virus. Henipaviruses may reflect a relatively easy target for broadly protective vaccines due to stringent requirements for the entry receptor EphB2, limited observed viral escape, and relatively low genetic diversity [<xref ref-type="bibr" rid="CR111">111</xref>].</p><p id="Par64">Influenza, on the other hand, embodies a target that is potentially even more challenging than coronaviruses, particularly due to its segmented genome, which allows reassortment in coinfected cells. This reassortment leads to antigenic shift, which is a major determinant of pandemic influenza strains. Influenza also has a broad host range and vast genetic diversity generated by error-prone replication and antigenic shift. Of the four types of influenza, only type A has caused human pandemics and can be zoonotic, while type B causes seasonal outbreaks and only circulates in humans.</p><p id="Par65">To counter this constant evolution, seasonal vaccines are redesigned annually on predictions of what will be the dominant circulating variants in the upcoming &#8216;flu season.&#8217; Predictions must be made significantly ahead of time owing to the time needed to manufacture sufficient doses of vaccine, which can lead to mismatches between vaccine and circulating strains that almost universally lead to limited efficacy.</p><p id="Par66">More than 800 pandemic influenza vaccines have been designed and reported, with only eight being described as universal or paninfluenza [<xref ref-type="bibr" rid="CR112">112</xref>]. A universal influenza vaccine would have to protect against currently circulating human and zoonotic strains and emerging variants resulting from antigenic drift and shift.</p><p id="Par67">Influenza is highly diverse in sequence. For influenza A, there are at least 18 hemagglutinin (HA) and 12 neuraminidase (NA) subtypes, with group 1 and group 2 species sharing only ~37% sequence homology for HA and NA proteins and only ~25% sequence homology with influenza B species (reviewed in ref. [<xref ref-type="bibr" rid="CR113">113</xref>]). Internal proteins such as the polymerase subunits (PA, PB1, PB2), matrix and nucleoprotein can have conservation in sequence of 77&#8211;97% within influenza A but much reduced conservation with influenza B species.</p><p id="Par68">Two conserved antigenic targets of interest for vaccinologists are the membrane-proximal stalk domain of HA [<xref ref-type="bibr" rid="CR114">114</xref>] and the ectodomain of the ion channel M2 [<xref ref-type="bibr" rid="CR115">115</xref>]. Paninfluenza A/B monoclonal nAbs, such as the HA-stem targeting CR9114, have shown protection in lethal heterosubtypic influenza challenge models. However, cross-subtype HA-stem antibody responses between H1N1 and H3N2 are limited due to differences in HA-stem glycosylation sites and low sequence conservation.</p><p id="Par69">Paninfluenza conserved T-cell epitopes, such as HLA-A*02-restricted PB<sub>1413&#8211;421,</sub> have been identified [<xref ref-type="bibr" rid="CR116">116</xref>]; however, these are often not immunodominant in natural infection. A vaccine based on conserved regions of M1 and NP within a modified vaccinia Ankara (MVA) vector showed encouraging immunogenicity data; however, it was not efficacious in humans [<xref ref-type="bibr" rid="CR117">117</xref>]. Recently, a mosaic VLP vaccine containing HA and NA antigens was shown to induce nAb and T cells that could recognize a broad range of seasonal influenza strains and could protect against lethal H1N1 and H3N2 challenge in mice [<xref ref-type="bibr" rid="CR118">118</xref>]. A vaccine based on conserved long peptides (Flu-v, PepTcell SEEK) was tested in a human challenge study with H1N1 challenge virus and reduced mild to moderate disease [<xref ref-type="bibr" rid="CR119">119</xref>].</p><p id="Par70">One important aspect of vaccine design is the durability of the protection. As with SARS-CoV-2 vaccines, immunity and efficacy have been observed to wane after influenza vaccination, with detectable loss even over the course of a flu season [<xref ref-type="bibr" rid="CR120">120</xref>]. Immunity induced by natural infection may be more long-lasting and can be life-long against certain strains [<xref ref-type="bibr" rid="CR121">121</xref>]. <italic toggle="yes">A better understanding of how T and B-cell responses evolve over time and the signals needed to prolong protective immunity could have an enormous impact across the spectrum of vaccines</italic>.</p><p id="Par71">What is encouraging, however, when thinking about the impact vaccination could have, is the apparent eradication of influenza A subtypes from the human population linked to cross-reactive immunity. On several occasions following pandemics, influenza A cross-reactive immunity has led to a level of protective herd immunity that has eliminated viral subtypes, including H1N1 in 1957, H2N2 in 1968, and seasonal H1N1 in 2009. Universal vaccines aim to recapitulate this type of durable cross-reactive immunity but on a broader scale and without the need for infection or symptomatic disease.</p><p id="Par72">Interestingly, the immunological phenomenon of original antigenic sin, where immune responses to subsequent similar but nonidentical antigens are dominated by less effective cross-reactive immunity rather than generating de novo highly specific and effective immunity, has been described for influenza. Protection against hemagglutinin subtypes similar to the strain circulating around the time of a cohort&#8217;s first influenza exposure as children appears to be stronger than against other subtypes, suggesting the strong influence of that first exposure on the immune response to all subsequent influenza exposures [<xref ref-type="bibr" rid="CR122">122</xref>&#8211;<xref ref-type="bibr" rid="CR124">124</xref>]. This raises the interesting question of whether vaccination prior to the first influenza infection can be tailored to shape a more broadly protective immune response throughout life [<xref ref-type="bibr" rid="CR125">125</xref>].</p><p id="Par73">It is anticipated that the development of a universal influenza vaccine will be an iterative process informed by continued studies into vaccine and natural infection correlates of protection.</p></sec><sec id="Sec20"><title>Pan-coronavirus vaccine approaches</title><p id="Par74">Despite decades of research and multiple approaches being pursued, there are no protective vaccines for highly variable viruses such as HIV, influenza and HCV [<xref ref-type="bibr" rid="CR126">126</xref>]. However, advances in our understanding of anti-viral immunity, cross-reactivity, and molecular mechanisms of vaccine-induced immunity offer renewed hope. In particular, advances in computational methods have had a profound impact on the way we measure immunity and design antigens for vaccines. Below, we will highlight some of the approaches (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref><bold>;</bold> Table&#160;<xref rid="Tab2" ref-type="table">2</xref>, <italic toggle="yes">preclinical;</italic> Table&#160;<xref rid="Tab3" ref-type="table">3</xref>, <italic toggle="yes">in clinical testing</italic>) that are currently being applied to coronavirus vaccines, including many novel approaches that could lead to paradigm shifts in vaccinology.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Graphic summary of next-generation approaches for broadly targeted and pan-coronavirus vaccines, including nanoparticle delivery; the use of mosaic antigens or serial vaccination to educate the immune system with multiple versions of a given viral protein; the use of novel regions of the virus, in particular conserved regions outside of spike; and finally, consensus sequence design or computational antigen design, to select the antigenic sequence that induces the most broadly reactive immunity. NP nucleoprotein, NSP non-structural protein, ORF open reading frame, RBD receptor binding domain,&#160;RTC replication-transcription complex.&#160;Created with BioRender.com</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1163" position="float" orientation="portrait" xlink:href="41423_2023_1116_Fig2_HTML.jpg"/></fig><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>A selection of next-generation pan-variant to pan-coronavirus vaccines undergoing preclinical testing</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sponsor/funder</th><th colspan="1" rowspan="1">Breadth of target</th><th colspan="1" rowspan="1">Vaccine platform</th><th colspan="1" rowspan="1">Vaccine name</th><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Adminstered</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Duke University</td><td colspan="1" rowspan="1">&#946;-coronavirus and Merbecovirus</td><td colspan="1" rowspan="1">Ferritin nanoparticle</td><td colspan="1" rowspan="1">RBD&#8211;scNP</td><td colspan="1" rowspan="1">RBD monovalent or trivalent</td><td colspan="1" rowspan="1">3M-052 alum</td><td colspan="1" rowspan="1">Intramuscular</td></tr><tr><td colspan="1" rowspan="1">Stanford University</td><td colspan="1" rowspan="1">Sarbecovirus</td><td colspan="1" rowspan="1">Ferritin nanoparticle</td><td colspan="1" rowspan="1">DCFHP</td><td colspan="1" rowspan="1">Spike (70 aa deleted)</td><td colspan="1" rowspan="1">Alhydrogel</td><td colspan="1" rowspan="1">Intramuscular</td></tr><tr><td colspan="1" rowspan="1">Caltech</td><td colspan="1" rowspan="1">Sarbecovirus</td><td colspan="1" rowspan="1">Mosaic nanoparticle</td><td colspan="1" rowspan="1">Mosaic-8</td><td colspan="1" rowspan="1">1 SARS-CoV-2 RBD + 7 sarbecovirus RBD</td><td colspan="1" rowspan="1">AddaVax</td><td colspan="1" rowspan="1">Intramuscular and Intraperitoneal</td></tr><tr><td colspan="1" rowspan="1">Caltech</td><td colspan="1" rowspan="1">Sarbecovirus</td><td colspan="1" rowspan="1">Quartet or Dual Quartet Nanocage</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">1 SARS-CoV-2 RBD + 7 sarbecovirus RBD</td><td colspan="1" rowspan="1">AddaVax</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">SK Bioscience, Uni of Washington, Uni of North Carolina at Chapel Hill</td><td colspan="1" rowspan="1">Sarbecovirus</td><td colspan="1" rowspan="1">Mosaic nanoparticle</td><td colspan="1" rowspan="1">RBD-NP or GBP511</td><td colspan="1" rowspan="1">RBD from: SARS-CoV-2 + SARS-CoV-1 + 2 serbecovirus</td><td colspan="1" rowspan="1">AS03</td><td colspan="1" rowspan="1">Intramuscular</td></tr><tr><td colspan="1" rowspan="1">Oragenics, Inspirevax, National Research Council of Canada</td><td colspan="1" rowspan="1">Pan-coronavirus</td><td colspan="1" rowspan="1">Protein subunit</td><td colspan="1" rowspan="1">NT-CoV2-1</td><td colspan="1" rowspan="1">SmT1v3 (version of SARS-CoV-2 spike)</td><td colspan="1" rowspan="1">BDX301</td><td colspan="1" rowspan="1">Intranasal</td></tr><tr><td colspan="1" rowspan="1">Francis Crick Institute</td><td colspan="1" rowspan="1">Pan-coronavirus</td><td colspan="1" rowspan="1">Protein subunit with DNA boost</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">S2</td><td colspan="1" rowspan="1">Monophosphoryl lipid A for protein</td><td colspan="1" rowspan="1">Intraperitoneal protein, Intramuscular and Intravenous DNA</td></tr><tr><td colspan="1" rowspan="1">INSERM Vaccine Research Institute</td><td colspan="1" rowspan="1">Sarbecovirus</td><td colspan="1" rowspan="1">Protein subunit</td><td colspan="1" rowspan="1">CD40.CoV2</td><td colspan="1" rowspan="1">RBD or Spike/NP conserved epitopes?</td><td colspan="1" rowspan="1">Anti-CD40 targeting</td><td colspan="1" rowspan="1">Intraperitoneal&#160;and Intramuscular</td></tr><tr><td colspan="1" rowspan="1">Valo Therapeutics Ltd</td><td colspan="1" rowspan="1">Pan-coronavirus</td><td colspan="1" rowspan="1">Adenovirus-based + HLA-matched peptides</td><td colspan="1" rowspan="1">PeptiVax</td><td colspan="1" rowspan="1">Spike + peptide (CD8 epitopes)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">OSIVAX</td><td colspan="1" rowspan="1">SARS-CoV1, SARS-CoV2</td><td colspan="1" rowspan="1">Virus-like particle oligoDOM</td><td colspan="1" rowspan="1">OVX033</td><td colspan="1" rowspan="1">NP (Wuhan)</td><td colspan="1" rowspan="1">Unadjuvanted or squalene-in-water emulsion</td><td colspan="1" rowspan="1">Intramuscular</td></tr><tr><td colspan="1" rowspan="1">Fudan University China</td><td colspan="1" rowspan="1">Sarbecovirus</td><td colspan="1" rowspan="1">Protein subunit - human IgG Fc-conjugated RBD</td><td colspan="1" rowspan="1">CF501</td><td colspan="1" rowspan="1">RBD-Fc</td><td colspan="1" rowspan="1">CF501 (sting agonist)</td><td colspan="1" rowspan="1">Intramuscular</td></tr><tr><td colspan="1" rowspan="1">University of California, Irvine</td><td colspan="1" rowspan="1">Pan-coronavirus</td><td colspan="1" rowspan="1">Viral vector AAV-9</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Multi-epitope</td><td colspan="1" rowspan="1">CXCL11 'prime-pull'</td><td colspan="1" rowspan="1">Subcutaneous and Intranasal</td></tr><tr><td colspan="1" rowspan="1">University of North Carolina at Chapel Hill</td><td colspan="1" rowspan="1">Sarbecovirus</td><td colspan="1" rowspan="1">Alphavirus</td><td colspan="1" rowspan="1">VRP3526-spike</td><td colspan="1" rowspan="1">Spike</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Footpad</td></tr><tr><td colspan="1" rowspan="1">University of Wisconsin/Madison</td><td colspan="1" rowspan="1">Pan-coronavirus</td><td colspan="1" rowspan="1">VLP nanoparticle</td><td colspan="1" rowspan="1">VLP-S2</td><td colspan="1" rowspan="1">S2</td><td colspan="1" rowspan="1">Various (AddaVax, Qs-21, AddaS03, pIC)</td><td colspan="1" rowspan="1">Subcutaneous</td></tr><tr><td colspan="1" rowspan="1">Universit&#228;tsmedizin Berlin</td><td colspan="1" rowspan="1">Pan-coronavirus</td><td colspan="1" rowspan="1">Non-integrating lentivirus</td><td colspan="1" rowspan="1">NILV-PanCoVac</td><td colspan="1" rowspan="1">T cell epitopes in structural proteins</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Intranasal</td></tr></tbody></table></table-wrap><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Highlights of next-generation pan-variant and pan-sarbecovirus vaccines undergoing early clinical testing</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sponsor/funder</th><th colspan="1" rowspan="1">Breadth of target</th><th colspan="1" rowspan="1">Trial number</th><th colspan="1" rowspan="1">Phase</th><th colspan="1" rowspan="1">Vaccine platform</th><th colspan="1" rowspan="1">Vaccine name</th><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Adminstered</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">WRAIR</td><td colspan="1" rowspan="1">Sarbecovirus</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04784767">NCT04784767</ext-link></td><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">Ferritin nanoparticle</td><td colspan="1" rowspan="1">SpFN_1B-06-PL</td><td colspan="1" rowspan="1">Spike</td><td colspan="1" rowspan="1">ALFQ</td><td colspan="1" rowspan="1">Intramuscular</td></tr><tr><td colspan="1" rowspan="1">DIOSynVax, PharmaJet, University of Southampton</td><td colspan="1" rowspan="1">Sarbecovirus</td><td colspan="1" rowspan="1">ISRCTN87813400</td><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">mRNA</td><td colspan="1" rowspan="1">pEVAC-PS</td><td colspan="1" rowspan="1">T2_17 (DIOSynVax generated)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Intradermal needle-free</td></tr><tr><td colspan="1" rowspan="1">VBI Vaccines Inc.</td><td colspan="1" rowspan="1">SARS-CoV-2, SARS-CoV, and MERS-CoV</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05548439">NCT05548439</ext-link></td><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">Enveloped virus-like particle (eVLP)</td><td colspan="1" rowspan="1">VBI-2901</td><td colspan="1" rowspan="1">Spike trivalent (SARS-CoV-1, SARS-CoV-2, MERS-CoV</td><td colspan="1" rowspan="1">Aluminum phosphate (Alum)</td><td colspan="1" rowspan="1">Intramuscular</td></tr><tr><td colspan="1" rowspan="1">Gristone Bio</td><td colspan="1" rowspan="1">Sarbecovirus/Pan-variant</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05148962">NCT05148962</ext-link></td><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">Self-amplifying mRNA</td><td colspan="1" rowspan="1">GRT-R910</td><td colspan="1" rowspan="1">Codon optimized, prefusion stabilized Spike + T cell epitopes</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Intramuscular</td></tr><tr><td colspan="1" rowspan="1">NIH</td><td colspan="1" rowspan="1">Pan-variant</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06026514">NCT06026514</ext-link></td><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">Live-attenuated bovine/human parainfluenza</td><td colspan="1" rowspan="1">B/HPIV3/S-2P</td><td colspan="1" rowspan="1">HexaPro Spike</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Nasal spray</td></tr><tr><td colspan="1" rowspan="1">Tetherex &amp; Mayo clinic</td><td colspan="1" rowspan="1">Pan-variant</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04839042">NCT04839042</ext-link></td><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">Single cycle Ad</td><td colspan="1" rowspan="1">SC-Ad6-1</td><td colspan="1" rowspan="1">Spike trivalent cocktail</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Intranasal and Inhaled</td></tr></tbody></table></table-wrap></p><sec id="Sec21"><title>Homotypic nanoparticle delivery</title><p id="Par75">Nanoparticles are nanoscale particulate structures that mimic the structural features of natural viruses (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). In recent years, the development of nanoparticle-based vaccines has benefitted from advances in material science that have led to improvements in antigen structure and stability, targeted vaccine delivery, and immunogenicity with good safety profiles. Nanoparticles can be used to encapsulate the viral antigen into the nanoparticle core (e.g., mRNA lipid nanoparticles), or they can present the antigen as protein on the surface of the nanoparticles (e.g., virus-like particles, protein nanoparticles).</p><p id="Par76">For example, nanoparticles have been constructed with individual or multiple versions of the full spike protein or RBD region and presented in high-order antigen arrays in native-like conformations (reviewed in ref. [<xref ref-type="bibr" rid="CR127">127</xref>]). Fusing naturally occurring bacterial ferritin to antigens as a vaccine delivery platform increases the immune response for weakly immunogenic targets and recapitulates the complex structure of trimeric class I glycoproteins. This makes <italic toggle="yes">ferritin nanoparticles</italic> a promising avenue to explore to generate enhanced immune responses. A group at the <italic toggle="yes">Walter Reed Army Institute of Research</italic>
<italic toggle="yes"><underline>(WRAIR)</underline></italic> created prefusion-stabilized <italic toggle="yes">S-trimer-ferritin nanoparticles (SpFNs)</italic>, which were shown to be stable candidate immunogens that elicited potent nAb titers against SARS-CoV-2 variants and robust protection against challenge in a K18-hACE2 mouse model [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR129">129</xref>] (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Heterologous prime-boost vaccine regimens combining SpFN with Johnson &amp; Johnson&#8217;s adenoviral vectored vaccine Ad26.COV2.S induced strong nAb and T-cell responses that protected mice from heterologous Omicron BA.5 challenge [<xref ref-type="bibr" rid="CR130">130</xref>].</p><p id="Par77">The immunogenicity of the RBD may be enhanced by presenting multiple copies of the RBD on a single particle to B cells, allowing multiple antigen-BCR engagements. A group based at <italic toggle="yes"><underline>Duke University</underline></italic> took a similar approach; they used self-assembling <italic toggle="yes">Helicobacter pylori</italic> ferritin nanoparticles with 24 copies of RBD attached via sortase A, named <italic toggle="yes">RBD&#8211;scNP</italic> [<xref ref-type="bibr" rid="CR131">131</xref>] (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Using the TLR7/8 agonist 3M-052 alum as an adjuvant, RBD-scNP was designed to be a pan-&#946;-coronavirus/merbecovirus vaccine. RBD-scNPs provided sterilizing immunity in the upper airways of macaques and induced nAbs that could cross-recognize bat WIV-1, bat SHC014, SARS-CoV-1, and pangolin COV GXP4L viruses [<xref ref-type="bibr" rid="CR131">131</xref>] as well as all SARS-CoV-2 variants tested [<xref ref-type="bibr" rid="CR132">132</xref>]. An updated trivalent version encoding the RBD from SARS-CoV-2, bat RSHC014, and MERS-CoV induced nAb to MERS-CoV and SARS-CoV-2 Omicron [<xref ref-type="bibr" rid="CR133">133</xref>]. This vaccine is being manufactured at the Duke Human Vaccine Institute for Phase-I testing in humans.</p><p id="Par78">Another ferritin nanoparticle-based vaccine is <italic toggle="yes">Delta-C70-Ferritin-HexaPro (DCFHP)</italic> from <italic toggle="yes"><underline>Stanford University</underline></italic>
<italic toggle="yes">(</italic>Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). It is based on S&#916;C-Fer, which displays a truncated form of the prefusion SARS-CoV-2 Wuhan-Hu-1 spike ectodomain trimer on self-assembling nanoparticles. Due to its use of a stabilized spike protein (HexaPro, discussed below), DCFHP is stable at temperatures ranging from 4 to 37&#8201;&#176;C for at least 14 days, making local distribution of this vaccine feasible without refrigeration [<xref ref-type="bibr" rid="CR134">134</xref>]. It also contains a deletion of 70 amino acid residues from the C-terminus, a region that is highly flexible and that contains an immunodominant linear epitope that is strongly targeted by non-nAbs in convalescent COVID-19 plasma. The removal of this region and the multivalent presentation on a ferritin nanoparticle significantly improved DCFHP&#8217;s neutralizing potency in mice relative to the use of unedited spike, since it allows the immune system to &#8216;not get distracted&#8217; by creating an antibody response against a region that is ultimately nonneutralizing [<xref ref-type="bibr" rid="CR134">134</xref>]. Wuhan-Hu-1 was specifically chosen to be expressed in the vaccine after the group reported that strain-specific mutations adversely altered the antigen structure, stability and immunogenicity [<xref ref-type="bibr" rid="CR135">135</xref>]. In both mice and rhesus macaques, a two-dose intramuscular immunization regimen resulted in durable, robust, and broad neutralization against all SARS-CoV-2 variants tested, including the Omicron subvariants BA.4/539 and BQ.140. Antisera from immunized macaques also showed durable neutralization against SARS-CoV-1.</p><p id="Par79">A collaboration between <italic toggle="yes"><underline>Oragenics, Inspirevax, and the National Research Council of Canada</underline></italic> has led to the development of <italic toggle="yes">NT-CoV-2</italic> (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). To mimic the trimerized conformation of the native SARS-CoV-2 spike glycoprotein more closely, they fused naturally trimerized human resistin to the spike ectodomain to generate a stable trimer protein antigen called SmT1. Immunized serum from mice vaccinated with SmT1 strongly blocked the binding of SARS-CoV-2 alpha and beta variants to cells [<xref ref-type="bibr" rid="CR136">136</xref>]. To engage mucosal immunity, a modified version of SmT1 was combined with the mucosal adjuvant BDX301 (named <italic toggle="yes">NT-CoV2-1</italic>). BALB/c mice immunized with NT-CoV2-1 generated strong IgA and IgG responses in both BAL and serum, as well as strong neutralization responses against SARS-CoV-2 variants [<xref ref-type="bibr" rid="CR137">137</xref>].</p><p id="Par80">The French vaccine company <italic toggle="yes"><underline>OSIVAX</underline></italic> has employed self-assembling nanoparticles to deliver the nucleocapsid protein (NP) rather than spike/RBD for the induction of T cells and binding antibodies, both of which have been associated with protection from severe disease in humans [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR138">138</xref>] (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Using the ancestral Wuhan-Hu-1 sequence NP in their vaccine <italic toggle="yes">OVX033</italic>, they showed cross-protection in mice against Delta and Omicron BA.1 strains [<xref ref-type="bibr" rid="CR139">139</xref>]. Vaccines using whole NPs have also been attempted with the Ad5 vector [<xref ref-type="bibr" rid="CR140">140</xref>].</p></sec><sec id="Sec22"><title>Mosaic antigen delivery</title><p id="Par81">Combining several RBD regions for presentation as a vaccine, especially from both humans and animal coronaviruses, increases the likelihood of eliciting cross-reactive antibody responses. A group from <italic toggle="yes"><underline>California Institute of Technology (Caltech)</underline></italic> has utilized a multivalent engineered protein domain called SpyCatcher to fuse antigens to virus-like particles. SpyCatcher003-mi3 nanoparticles that display RBDs from both human and animal coronaviruses were prepared to evaluate the effectiveness of mosaic particles in producing cross-reactive antibody responses (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). RBDs from Bat CoV RaTG13, Bat CoV SHC014, Bat CoV Rs4081, Bat CoV RmYN02, Bat CoV Rf1, Bat CoV WIV1, Pangolin CoV Pang17, and SARS-CoV-2 were expressed on SpyTag proteins, which were then fused to one SpyCatcher protein with multiple domains, leading to the generation of the <italic toggle="yes">mosaic-8b</italic> nanoparticle vaccine [<xref ref-type="bibr" rid="CR141">141</xref>].</p><p id="Par82">Although there was no significant difference in the magnitude of the <italic toggle="yes">total</italic> anti&#8211;SARS-CoV-2 IgG responses between homotypic and mosaic immunizations, more <italic toggle="yes">cross-reactive</italic> antibody responses were observed for mosaic-8b immunizations [<xref ref-type="bibr" rid="CR142">142</xref>]. For instance, mosaic-8b vaccination induced nAb responses to SARS-CoV-1 despite its RBD not being included in the vaccine [<xref ref-type="bibr" rid="CR141">141</xref>]. Moreover, mosaic-8b protected against SARS-CoV-2 Delta as well as SARS-CoV-1 challenge in nonhuman primates [<xref ref-type="bibr" rid="CR142">142</xref>]. Monoclonal antibodies (mAbs) capable of neutralizing human and animal sarbecoviruses and SARS-CoV-2 variants could be isolated from mosaic-8b-vaccinated mice [<xref ref-type="bibr" rid="CR143">143</xref>].</p><p id="Par83">Due to challenges in scaling the production of 9 different vaccine components, the group is currently developing <italic toggle="yes">quartet nanocages</italic> encoding RBDs from SHC014, Rs4081, RaTG13 and SARS-CoV-2 Wuhan-Hu-1 (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Instead of one RBD type occupying a domain, each domain is occupied by all four RBD types in a quartet nanocage. Quartet nanocage immunizations were able to induce antibody responses in mice to diverse sarbecoviruses, although with less breadth than mosaic-8b vaccination [<xref ref-type="bibr" rid="CR144">144</xref>]. The development and testing of nanocages is ongoing to ensure readiness for clinical trials.</p><p id="Par84"><italic toggle="yes"><underline>Washington University and SK Biosciences</underline></italic> took a similar approach, genetically fusing SARS-CoV-2 RBD on the exterior surface of the two-component protein nanoparticle I53-50, which is a computationally designed 120-subunit complex with icosahedral symmetry constructed from trimeric (I53-50A) and pentameric (I53-50B) components. RBDs from SARS-CoV-2, SARS-CoV-1, bat CoV RaTG13, and bat CoV WIV1 were genetically fused using linkers to I53-50A, allowing the display of 60 RBDs in a trimeric form in a vaccine named <italic toggle="yes">RBD-NP or GBP511</italic> [<xref ref-type="bibr" rid="CR145">145</xref>] (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Serum from RBD-NP-immunized nonhuman primates strongly cross-reacted with Pangolin-GD and RaTG13 RBDs but had weaker binding to distantly related RmYN02, SARS-CoV-1, WIV16, and ZXC21 RBDs [<xref ref-type="bibr" rid="CR146">146</xref>]. Fifteen broadly neutralizing mAbs were isolated from macaques that could neutralize a panel of pseudoviruses carrying spike proteins of SARS-CoV-2 variants, including Omicron BA.1 and BA.4/5, and SARS-CoV-1 [<xref ref-type="bibr" rid="CR147">147</xref>].</p><p id="Par85"><italic toggle="yes"><underline>VBI Vaccines</underline></italic> is a biopharmaceutical company developing vaccines that mimic the natural presentation of the virus to elicit innate immune responses, such as with their proprietary enveloped virus-like particle (eVLP) technology (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). They used this technology to design <italic toggle="yes">VBI-2901</italic>, a vaccine that expresses a modified prefusion form of spike proteins from SARS-CoV-2, SARS-CoV-1, and MERS-CoV. Mice vaccinated with VBI-2901 elicited a strong neutralization response against all variants and Bat RaTG13. Compared to its sister vaccine VBI-2902, which only contains the ancestral Wuhan-Hu-1 spike, VBI-2901 generated a 2.5-fold stronger response to the ancestral strain and a ninefold stronger response against the bat coronavirus [<xref ref-type="bibr" rid="CR148">148</xref>]. VBI-2901 is being examined in Phase-I trials.</p><p id="Par86">Interestingly, some mosaic vaccines employ organized repeated patterns of antigens, such as RBD-NP/GBP511, while others use randomly distributed antigens, such as mosaic-8b. In theory, random distribution should preferentially engage cross-reactive B cells that can cross-recognize multiple versions of RBD/spike proteins next to each other on the nanoparticle. However, it remains unclear which approach is most effective.</p></sec><sec id="Sec23"><title>Serial vaccination</title><p id="Par87">Rather than trying to present multiple antigens together in the form of a mosaic vaccine to the immune system, an alternative approach could be to sequentially vaccinate with different antigens in a series in an attempt to boost the most cross-reactive immunity (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Groups at <italic toggle="yes"><underline>Yale University</underline></italic> tested this approach with their lipid nanoparticle <italic toggle="yes">(LNP)-mRNA</italic> vaccines encoding the full-length spike of SARS-CoV-2 Delta, SARS-CoV-1, and MERS-CoV. A direct comparison in mice demonstrated that sequential prime-boost vaccination with their three constructs (6 vaccinations in total) induced a stronger antibody response than simultaneous vaccination (prime and then boost with a mixture of all three, 2 vaccinations in total) [<xref ref-type="bibr" rid="CR149">149</xref>]. It is not surprising that separating the vaccines over time leads to a stronger response; however, there was also some indication that it induced greater cross-reactivity and durability of the immune response [<xref ref-type="bibr" rid="CR149">149</xref>]. It would be interesting to see if a longer time interval between vaccinations than the 3 weeks employed in this study changes the magnitude and type of immune response generated, as it does when reboosting with Ad/MVA encoding HCV antigens [<xref ref-type="bibr" rid="CR150">150</xref>].</p></sec><sec id="Sec24"><title>Consensus sequence</title><p id="Par88">One approach that has been taken is to design vaccine antigens that are enriched for conserved T and B-cell epitopes either as a consensus sequence (which is the closest natural circulating sequence to a bioinformatically calculated consensus) or as a string of epitopes taken out of their natural context within the viral protein (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par89">A number of epitopes from structural and nonstructural viral proteins conserved across a curated subset of &#946;-coronaviruses (human and animal [<xref ref-type="bibr" rid="CR100">100</xref>]) have been combined into an antigen for delivery in an adeno-associated viral vector that has shown pan-SARS-CoV-2 variant protection in mice [<xref ref-type="bibr" rid="CR151">151</xref>]. Interestingly, T-cell responses to the 22 conserved epitopes within this vaccine were enriched in individuals with asymptomatic infections relative to individuals with symptomatic infection [<xref ref-type="bibr" rid="CR151">151</xref>].</p></sec><sec id="Sec25"><title>Computational identification of cross-reactive immunogens</title><p id="Par90">An important and exciting emerging field in vaccinology is the use of computationally designed vaccine antigens rather than a circulating viral sequence (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Several different approaches are being tested to bioinformatically design novel antigen sequences using large amounts of viral sequencing data integrated with other sources of information, such as mapped epitopes and protein structures. These antigens aim to outperform any sequences selected from a circulating virus in their induction of broadly protective immunity, often by targeting the immune response to conserved but subdominant epitopes.</p><p id="Par91">The most clinically advanced approach is that taken by <italic toggle="yes"><underline>DIOSynVax</underline></italic> (Digitally Immune Optimised Synthetic Vaccines), who have partnered with PharmaJet for a first-in-human needle-free intradermal vaccine <italic toggle="yes">pEVAC-PS</italic> encoding their synthetic antigen T2_17 based on coronavirus RBD sequences (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>) [<xref ref-type="bibr" rid="CR152">152</xref>]. DIOSynVax&#8217;s approach is a viral-genome-informed method that creates an antigen sequence that is as similar as possible to all inputted sequences from a phylogenetic perspective&#8212;in this case, representative sequences for all known sarbecoviruses. This sequence is modified to ensure that key antibody epitopes are retained. Their antigen has been tested using several different platforms, including DNA, MVA and mRNA. Despite being designed before the emergence of several variants, including Delta and Omicron, the antigen induces cross-reactive nAb to these and several tested sarbecoviruses in mice, rabbits, and guinea pigs [<xref ref-type="bibr" rid="CR152">152</xref>].</p><p id="Par92">Relatedly, Hie et al. used machine learning language models to &#8220;learn&#8221; the language of viral escape. They have applied their constrained semantic change search framework to the analysis of escape to influenza A HA, HIV envelope, and SARS-CoV-2 spike to learn structural patterns of antibody escape [<xref ref-type="bibr" rid="CR152">152</xref>]. This could lead to the prediction of future escape variants and the design of vaccine antigens that encode structural epitopes that are more difficult to escape.</p><p id="Par93">An alternative approach to identifying conserved regions by comparing linear viral sequences is to use structural information on how regions interact in the 3D structure of the viral protein. This can identify &#8220;networked&#8221; regions that are so essential to a protein&#8217;s structure that they cannot be mutated without loss of structure and functionality [<xref ref-type="bibr" rid="CR153">153</xref>]. Nathan et al. used this approach to identify CD8 epitopes within mutation-resistant networked regions that were commonly targeted in convalescent individuals [<xref ref-type="bibr" rid="CR153">153</xref>].</p></sec><sec id="Sec26"><title>Combining T-cell and antibody antigens in one vaccine</title><p id="Par94">Although many of the vaccine approaches discussed above will induce both T and B cells, it is often difficult to fully optimize the vaccine platform and immunogen itself for both T and B-cell engagement. However, several approaches are being tested, including the combination of separate antigens to elicit both T and B-cell responses. For instance, once they are identified, short sequences corresponding to broadly conserved CD4 and CD8 epitopes can often be added to vaccines encoding carefully designed structural antigens that are used to elicit B-cell responses. Charged nonreplicative adenoviruses that encode the full-length spike for antibody induction (analogous to AZD1222) have been coated with peptides corresponding to conserved CD8 T-cell epitopes [<xref ref-type="bibr" rid="CR154">154</xref>].</p><p id="Par95"><italic toggle="yes"><underline>Gritstone Biotech</underline></italic> employed Venezuelan equine encephalitis virus-based self-amplifying mRNA vector in a lipid nanoparticle called <italic toggle="yes">GRT-R910</italic> encoding both the prefusion stabilized full-length SARS-CoV-2 spike and additional conserved T-cell epitopes from ORF3a, NP and membrane (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Self-amplifying mRNA generates high and more durable expression of the encoded coronavirus antigens, which could translate to greater immunogenicity than nonamplifying mRNA vaccines [<xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR156">156</xref>]. GRT-R910 protected against SARS-CoV-2 infection in macaques when used as a homologous prime-boost or as a single boost to a chimpanzee adenovirus-encoded spike [<xref ref-type="bibr" rid="CR157">157</xref>]. Encouraging results have been published for Phase-I in healthy adults aged &gt;60, showing nAb responses to SARS-CoV-2 Beta, Delta, and Omicron BA.1 at 6 months after GRT-R910 vaccination administered as a booster 19-31 weeks after a primary vaccination series with AZD1222 (ChAdOx1-spike) [<xref ref-type="bibr" rid="CR158">158</xref>]. GRT-R910 also expanded the breadth and magnitude of the T-cell response to all antigens included. A 10,000-participant Phase-IIb trial will be conducted as part of the COVID-19 Prevention Network.</p></sec><sec id="Sec27"><title>Other noteworthy approaches</title><p id="Par96">In addition to adjusting the immunogen sequence itself, using more immunogenic vaccine delivery platforms and adjuvants could enhance the total coronavirus-specific immune responses generated, boosting broadly targeted responses. For instance, an IgG-Fc conjugated ancestral Wuhan-Hu-1 RBD sequence adjuvanted with a novel STING agonist CF501 induced potent nAb activity against SARS-CoV-2 Omicron and XBB variants in macaques, mice, and rabbits [<xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR160">160</xref>] (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par97">Similarly, during a malaria vaccine research program in 1986, WRAIR developed the adjuvant ALFQ, which consists of liposomes containing saturated phospholipids, cholesterol, monophosphoryl A and saponin QS21, which have been proven to be potent and safe [<xref ref-type="bibr" rid="CR161">161</xref>]. ALFQ-adjuvanted SpFNs elicit superior binding and neutralization responses and a stronger, more polyfunctional Th1 response than the adjuvant Alhydrogel in mice and macaques [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR163">163</xref>].</p><p id="Par98">A rather simple but very effective method of removing dominant epitopes to enhance&#160;responses to conserved subdominant epitopes involved the removal of the S1 portion of spike containing the RBD and then the administration of a vaccine with only S2 as a DNA vaccine or protein [<xref ref-type="bibr" rid="CR73">73</xref>] (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). The responses to S2 were&#160;stronger than when full-length spike was used as the antigen; furthermore, the S2-only vaccine was shown to induce nAb to both &#945;- and &#946;- coronaviruses (presumably to the fusion peptide as has been described in humans [<xref ref-type="bibr" rid="CR69">69</xref>]), and it boosted a more broadly targeting antibody response overall than repeated homologous full-length spike vaccines [<xref ref-type="bibr" rid="CR73">73</xref>]. Moreover, nonneutralizing binding antibodies to S2 have been linked to vaccine-mediated protection in a murine model using an alphavirus vectored pan-sarbecovirus [<xref ref-type="bibr" rid="CR72">72</xref>]. Virus-like particles encoding S2 have also been tested and could induce nAbs to all human coronaviruses in Syrian hamsters (HCoV, SARS-CoV-1 and SARS-CoV-2 variants) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). VLP-S2 reduced viral replication in respiratory tissues in hamsters challenged with SARS-CoV-2 Beta, Delta, and Omicron BA.1 variants and against a pangolin coronavirus [<xref ref-type="bibr" rid="CR164">164</xref>].</p><p id="Par99">Structure-guided spike design has also been used to identify artificial substitutions in the spike sequence that can <italic toggle="yes">increase the expression, solubility, and stability</italic> of spike (termed HexaPro) for use as a vaccine antigen [<xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR166">166</xref>]. This HexaPro antigen was used in a regimen termed &#8220;prime and spike&#8221;, in which a priming dose was administered intramuscularly to induce peripheral immune memory and a boosting dose was administered intranasally to expand and recruit spike-specific T and B cells to the mucosa [<xref ref-type="bibr" rid="CR167">167</xref>]. This approach laid down tissue-resident immunity within the respiratory mucosa, with the hope of offering more rapid and efficacious recall responses on exposure to sarbecoviruses. Intranasal delivery using a lung-tropic adeno-associated virus 9 vector to prime and chemokine pull (CXCL11) effectively induced SARS-CoV-2-specific lung-resident T cells and offered better protection against SARS-CoV-2 in mice [<xref ref-type="bibr" rid="CR168">168</xref>] (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Alternative technologies for administering vaccines may yield greater mucosal targeting of immunity. For example, a live-attenuated parainfluenza vectored spike vaccine (B/HPIV3/S-6P) will be tested using a nasal spray for mucosal targeting after promising results were observed in nonhuman primates and hamsters [<xref ref-type="bibr" rid="CR169">169</xref>, <xref ref-type="bibr" rid="CR170">170</xref>] (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). The research company ISR has developed an inhaled dry powder vaccine that does not require needles of cold chains [<xref ref-type="bibr" rid="CR171">171</xref>], and researchers at Yonsei University have developed a sublingual dissolving microneedle [<xref ref-type="bibr" rid="CR172">172</xref>]. Both of these vaccines use ancestral SARS-CoV-2 S1 antigens (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par100">The American pharmaceutical company <italic toggle="yes"><underline>Tetherex and the Mayo Clinic</underline></italic> developed a replicating adenoviral vector (<italic toggle="yes">SC-Ad6-1</italic>) that encodes a full-length spike; this vaccine is administered intranasally, and it aims to induce mucosal immunity [<xref ref-type="bibr" rid="CR173">173</xref>] (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). The single-cycle adenovirus replicates its genome (including the encoded spike transgene) 10,000 times but does not produce infectious virions. SC-Ad6-1 was shown to produce 100-fold more spike protein and provided better protection in hamsters than a replication-defective Ad [<xref ref-type="bibr" rid="CR173">173</xref>]. SC-Ad6-1 has entered Phase-I testing in Australia.</p><p id="Par101">Few of the vaccines described above have been tested in challenge models against viruses other than SARS-CoV-2 or have had the breadth of cross-reactive immunity they elicit rigorously tested against the full spectrum of coronaviruses. However, with multiple novel and exciting approaches to antigen design and delivery in testing, we are likely to obtain considerable knowledge regarding cross-protective immunity and the feasibility of pan-coronavirus vaccines.</p></sec></sec><sec id="Sec28"><title>Conclusions and perspectives</title><p id="Par102">A major challenge of developing vaccines against variable viruses, such as coronaviruses, is the difficulty in inducing immunity that cross-recognizes and protects against the full spectrum of possible viral variants while also limiting the opportunity for immune escape. As a result, considerable attention is being devoted to both&#160;the type of antigens included in a vaccine, as well as the sequence of antigenic targets. In particular, computational approaches, including bioinformatics and machine learning, are being used to better define sequence diversity/conservation across viruses and to aid in antigen design.</p><p id="Par103">Whereas first-generation vaccines rely mainly on spike, there is strong evidence that adaptive immunity to nonspike antigens contributes to protection from infection and disease in natural infection. This comprehensive immune response should be exploited in next-generation vaccines to complement antibodies in the global population, which is currently overwhelmingly seropositive against SARS-CoV-2 spike following vaccination and/or infection. In particular, T-cell antigens outside of spikes may be important for achieving early targeting of viral replication and broad reactivity [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. Furthermore, how to combine these different antigens or epitope strings into a single vaccine is not a trivial question. There is much to be learned about how antigen processing and flanking sequences influence antigen presentation and how responses to different epitopes interact to determine immunodominance.</p><p id="Par104">Further research is needed to elucidate the basic mechanism underpinning T and B-cell recruitment into an immune response, to examine antibody affinity maturation and to identify the determinants of the immunodominance hierarchy for T and B-cell epitopes, which ultimately may enable vaccine antigens to be rationally designed to induce broadly targeted immunity. A greater understanding of the correlates of protection against infection and disease is needed, particularly for T-cell responses, which are understudied due to the requirement for large sample volumes and the use of low-throughput assays. It is difficult to design a vaccine that can induce both strong antibody and T-cell responses, but it is likely that a coordinated effort employing both arms of the adaptive immune response will be most effective. Combinations of immunogenic vaccines, for instance, in heterologous prime-boost regimens, multiplexed vaccines, or serial vaccination, may be the key to achieving robust and durable immunity.</p><p id="Par105">It remains unclear whether true pan-coronavirus immunity exists. Research is ongoing to determine whether individual or combined T or B-cell responses can recognize the breadth of human coronaviruses. Testing vaccine approaches and challenging the immune system with a range of viruses is the only way to determine how cross-protective immunity can be. Different research groups and funders have different priorities, ranging from more immediate protection against all variants of single species, such as SARS-CoV-2, to the long-term ambitious goal of protection against future pandemics. Fortunately, we have a panel of novel tools and approaches that can be tested against these different goals in their respective time scales.</p><p id="Par106">The list of emergent viruses of concern issued by the WHO contains &#8220;disease X&#8221;, which underlines the importance of developing modular antiviral and vaccine technologies where minimal reprogramming is needed to redirect the platform to a newly emerging pathogen. One approach could be to design a suite of candidate pan-family vaccines, such as pan-coronavirus vaccines, that can be rolled out rapidly in the event of a new viral emergence to identify the candidate that best covers the novel human virus.</p><p id="Par107">The durability of vaccine protection is another key area that requires a better understanding of the fundamentals of immune memory, a key question being &#8220;<italic toggle="yes">how can we limit the acute contraction of the adaptive immune response after prophylactic vaccination and limit attrition of long-term memory</italic>, in particular for nAb titers in the blood?&#8221;.</p><p id="Par108">Another difficulty associated with vaccination against viruses targeting the upper respiratory tract is the generation of long-lasting mucosal immunity. Mechanistic studies in animal models suggest that mucosal targeting is likely to offer better protection against respiratory infections [<xref ref-type="bibr" rid="CR43">43</xref>], but methods for inducing mucosal immunity are in the earliest stages of testing. The route of vaccine administration could be critical, with intranasal, aerosolized, subinguinal and oral approaches being tested; however, immunogenicity may be hampered owing to the natural immune barriers present at these sites.</p><p id="Par109">Better animal models are needed in order to recapitulate human disease, diverse antigenic history (mixed infection and vaccination) and immune phenomena such as original antigenic sin and imprinting. Due to unpredictable rates of infection and diverse antigenic history, it is challenging to identify cohorts in which vaccine efficacy can be determined. The use of controlled human infections is an exciting area that has yielded new insights into the natural immune response to coronaviruses [<xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR175">175</xref>].</p><p id="Par110">Now is the right time to develop a pan-coronavirus vaccine due to advances in vaccine technologies, scalability, and immunogenicity, as well as our greater understanding of protective and cross-reactive immunity. Progress will be iterative, but with each new vaccine design, we are learning more about the feasibility of universal vaccines and how best to achieve this goal.</p></sec></body><back><fn-group><fn><p>These authors contributed equally: S. Cankat, M. U. Demael.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Prof. Mala Maini for her valuable input on manuscript drafts, Hilda Bastian for her informative blog posts (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://absolutelymaybe.plos.org/">https://absolutelymaybe.plos.org/</ext-link>), the R&amp;D Blue Print team at the WHO (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link>) and COVID-NMA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://covid-nma.com/vaccines/mapping/">https://covid-nma.com/vaccines/mapping/</ext-link>) for collating information on coronavirus vaccines.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>LS, UD, and SC jointly researched and wrote this review. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>LS is funded by a Rosetrees Trust and Pears Foundation Advancement Fellowship, SC is funded by a BBSRC LIDo-DTP PhD studentship (BB/T008709/1) and UD is funded by an MRC DTP PhD studentship (MR/W006774/1). LS has received funding from the UCL Therapeutic. Acceleration Support scheme supported by funding from MRC IAA 2021 UCL MR/X502984/1.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par111">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organisation, WHO Coronavirus (COVID-19) dashboard. 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://covid19.who.int">https://covid19.who.int</ext-link>. Accessed 27 Oct 2023.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Barnsley</surname><given-names>G</given-names></name><name name-style="western"><surname>Toor</surname><given-names>J</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>AB</given-names></name><name name-style="western"><surname>Winskill</surname><given-names>P</given-names></name><name name-style="western"><surname>Ghani</surname><given-names>AC</given-names></name></person-group><article-title>Global impact of the first year of COVID-19 vaccination: a mathematical modelling study</article-title><source>Lancet Infect Dis</source><year>2022</year><volume>22</volume><fpage>1293</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00320-6</pub-id><pub-id pub-id-type="pmid">35753318</pub-id><pub-id pub-id-type="pmcid">PMC9225255</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>S</given-names></name><name name-style="western"><surname>Hill</surname><given-names>EM</given-names></name><name name-style="western"><surname>Dyson</surname><given-names>L</given-names></name><name name-style="western"><surname>Tildesley</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Keeling</surname><given-names>MJ</given-names></name></person-group><article-title>Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>2416</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-02064-y</pub-id><pub-id pub-id-type="pmid">36302894</pub-id><pub-id pub-id-type="pmcid">PMC9671807</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cable</surname><given-names>J</given-names></name><name name-style="western"><surname>Jaykus</surname><given-names>L-A</given-names></name><name name-style="western"><surname>Hoelzer</surname><given-names>K</given-names></name><name name-style="western"><surname>Newton</surname><given-names>J</given-names></name><name name-style="western"><surname>Torero</surname><given-names>M</given-names></name></person-group><article-title>The impact of COVID-19 on food systems, safety, and security&#8212;a symposium report</article-title><source>Ann NY Acad Sci</source><year>2021</year><volume>1484</volume><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/nyas.14482</pub-id><pub-id pub-id-type="pmid">32860255</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z-R</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>YW</given-names></name><name name-style="western"><surname>Li</surname><given-names>FX</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Lin</surname><given-names>TF</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>ZY</given-names></name><etal/></person-group><article-title>Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials</article-title><source>Lancet Microbe</source><year>2023</year><volume>4</volume><fpage>e236</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(22)00390-1</pub-id><pub-id pub-id-type="pmid">36868258</pub-id><pub-id pub-id-type="pmcid">PMC9974155</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiersinga</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>AC</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>HC</given-names></name></person-group><article-title>Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a Review</article-title><source>JAMA</source><year>2020</year><volume>324</volume><fpage>782</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.12839</pub-id><pub-id pub-id-type="pmid">32648899</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>HE</given-names></name><name name-style="western"><surname>McCorkell</surname><given-names>L</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>JM</given-names></name><name name-style="western"><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>Long COVID: major findings, mechanisms and recommendations</article-title><source>Nat Rev Microbiol</source><year>2023</year><volume>21</volume><fpage>133</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00846-2</pub-id><pub-id pub-id-type="pmid">36639608</pub-id><pub-id pub-id-type="pmcid">PMC9839201</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altmann</surname><given-names>DM</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Joy</surname><given-names>G</given-names></name><name name-style="western"><surname>Otter</surname><given-names>AD</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pade</surname><given-names>C</given-names></name><etal/></person-group><article-title>Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity</article-title><source>Nature Communications</source><year>2023</year><volume>14</volume><fpage>5139</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40460-1</pub-id><pub-id pub-id-type="pmid">37612310</pub-id><pub-id pub-id-type="pmcid">PMC10447583</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>J</given-names></name><name name-style="western"><surname>Wood</surname><given-names>J</given-names></name><name name-style="western"><surname>Jaycox</surname><given-names>JR</given-names></name><name name-style="western"><surname>Dhodapkar</surname><given-names>RM</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P</given-names></name><name name-style="western"><surname>Gehlhausen</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Distinguishing features of long COVID identified through immune profiling</article-title><source>Nature</source><year>2023</year><volume>623</volume><fpage>139</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06651-y</pub-id><pub-id pub-id-type="pmid">37748514</pub-id><pub-id pub-id-type="pmcid">PMC10620090</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Surveillance of influenza and other seasonal respiratory viruses in the UK, winter 2022 to 2023. 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/statistics/annual-flu-reports/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-the-uk-winter-2022-to-2023">https://www.gov.uk/government/statistics/annual-flu-reports/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-the-uk-winter-2022-to-2023</ext-link>. Accessed 27 Oct 2023.</mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fendrick</surname><given-names>AM</given-names></name><name name-style="western"><surname>Monto</surname><given-names>AS</given-names></name><name name-style="western"><surname>Nightengale</surname><given-names>B</given-names></name><name name-style="western"><surname>Sarnes</surname><given-names>M</given-names></name></person-group><article-title>The economic burden of non-influenza-related viral respiratory tract infection in the United States</article-title><source>Arch Intern Med</source><year>2003</year><volume>163</volume><fpage>487</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1001/archinte.163.4.487</pub-id><pub-id pub-id-type="pmid">12588210</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>AR</given-names></name><name name-style="western"><surname>Shi</surname><given-names>WQ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>XL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Epidemiology and evolution of Middle East respiratory syndrome coronavirus, 2012-2020</article-title><source>Infect Dis Poverty</source><year>2021</year><volume>10</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1186/s40249-021-00853-0</pub-id><pub-id pub-id-type="pmid">33964965</pub-id><pub-id pub-id-type="pmcid">PMC8105704</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosaeed</surname><given-names>M</given-names></name><name name-style="western"><surname>Balkhy</surname><given-names>HH</given-names></name><name name-style="western"><surname>Almaziad</surname><given-names>S</given-names></name><name name-style="western"><surname>Aljami</surname><given-names>HA</given-names></name><name name-style="western"><surname>Alhatmi</surname><given-names>H</given-names></name><name name-style="western"><surname>Alanazi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial</article-title><source>Lancet Microbe</source><year>2022</year><volume>3</volume><fpage>e11</fpage><lpage>e20</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(21)00193-2</pub-id><pub-id pub-id-type="pmid">34751259</pub-id><pub-id pub-id-type="pmcid">PMC8565931</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Office, U.H.S.A.P. 2023 Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/news/jcvi-advises-on-eligible-groups-for-2023-autumn-booster">https://www.gov.uk/government/news/jcvi-advises-on-eligible-groups-for-2023-autumn-booster</ext-link>.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balloux</surname><given-names>F</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C</given-names></name><name name-style="western"><surname>Swadling</surname><given-names>L</given-names></name><name name-style="western"><surname>Richard</surname><given-names>D</given-names></name><name name-style="western"><surname>Jenner</surname><given-names>C</given-names></name><name name-style="western"><surname>Maini</surname><given-names>M</given-names></name><etal/></person-group><article-title>The past, current and future epidemiological dynamic of SARS-CoV-2</article-title><source>Oxford Open Immunol</source><year>2022</year><volume>20</volume><fpage>iqac003</fpage><pub-id pub-id-type="doi">10.1093/oxfimm/iqac003</pub-id><pub-id pub-id-type="pmcid">PMC9278178</pub-id><pub-id pub-id-type="pmid">35872966</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dejnirattisai</surname><given-names>W</given-names></name><name name-style="western"><surname>Huo</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><name name-style="western"><surname>Zahradn&#237;k</surname><given-names>J</given-names></name><name name-style="western"><surname>Supasa</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>467</fpage><lpage>84.e415</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.12.046</pub-id><pub-id pub-id-type="pmid">35081335</pub-id><pub-id pub-id-type="pmcid">PMC8723827</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhlmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>CK</given-names></name><name name-style="western"><surname>Claassen</surname><given-names>M</given-names></name><name name-style="western"><surname>Maponga</surname><given-names>T</given-names></name><name name-style="western"><surname>Burgers</surname><given-names>WA</given-names></name><name name-style="western"><surname>Keeton</surname><given-names>R</given-names></name><etal/></person-group><article-title>Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>625</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00090-3</pub-id><pub-id pub-id-type="pmid">35063123</pub-id><pub-id pub-id-type="pmcid">PMC8765759</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><name name-style="western"><surname>Zai</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Challenges and developments in universal vaccine design against SARS-CoV-2 variants</article-title><source>npj Vaccines</source><year>2022</year><volume>7</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00597-4</pub-id><pub-id pub-id-type="pmid">36535982</pub-id><pub-id pub-id-type="pmcid">PMC9761649</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Ge</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LF</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z</given-names></name></person-group><article-title>Bat origin of human coronaviruses</article-title><source>Virol J</source><year>2015</year><volume>12</volume><fpage>221</fpage><pub-id pub-id-type="doi">10.1186/s12985-015-0422-1</pub-id><pub-id pub-id-type="pmid">26689940</pub-id><pub-id pub-id-type="pmcid">PMC4687304</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;nchez</surname><given-names>CA</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>KL</given-names></name><name name-style="western"><surname>Zambrana-Torrelio</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LF</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name><etal/></person-group><article-title>A strategy to assess spillover risk of bat SARS-related coronaviruses in Southeast Asia</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>4380</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-31860-w</pub-id><pub-id pub-id-type="pmid">35945197</pub-id><pub-id pub-id-type="pmcid">PMC9363439</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatcher</surname><given-names>EL</given-names></name><name name-style="western"><surname>Zhdanov</surname><given-names>SA</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Blinkova</surname><given-names>O</given-names></name><name name-style="western"><surname>Nawrocki</surname><given-names>EP</given-names></name><name name-style="western"><surname>Ostapchuck</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Virus variation resource&#8212;improved response to emergent viral outbreaks</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><fpage>D482</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1065</pub-id><pub-id pub-id-type="pmid">27899678</pub-id><pub-id pub-id-type="pmcid">PMC5210549</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Silva CS, Mullis LB, Pereira O J.r, Saif LJ, Vlasova A, Zhang X, et al. Human respiratory coronaviruses detected in patients with influenza-like illness in Arkansas, USA. Virol Mycol. 2014;(Suppl 2):004.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4172/2161-0517.S2-004</pub-id><pub-id pub-id-type="pmcid">PMC5004774</pub-id><pub-id pub-id-type="pmid">27588218</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlasova</surname><given-names>AN</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Damtie</surname><given-names>D</given-names></name><name name-style="western"><surname>Xiu</surname><given-names>L</given-names></name><name name-style="western"><surname>Toh</surname><given-names>TH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Novel canine coronavirus isolated from a hospitalized patient with pneumonia in East Malaysia</article-title><source>Clin Infect Dis</source><year>2022</year><volume>74</volume><fpage>446</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab456</pub-id><pub-id pub-id-type="pmid">34013321</pub-id><pub-id pub-id-type="pmcid">PMC8194511</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lednicky</surname><given-names>JA</given-names></name><name name-style="western"><surname>Tagliamonte</surname><given-names>MS</given-names></name><name name-style="western"><surname>White</surname><given-names>SK</given-names></name><name name-style="western"><surname>Elbadry</surname><given-names>MA</given-names></name><name name-style="western"><surname>Alam</surname><given-names>MM</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Independent infections of porcine deltacoronavirus among Haitian children</article-title><source>Nature</source><year>2021</year><volume>600</volume><fpage>133</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04111-z</pub-id><pub-id pub-id-type="pmid">34789872</pub-id><pub-id pub-id-type="pmcid">PMC8636265</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandler</surname><given-names>JC</given-names></name><name name-style="western"><surname>Bevins</surname><given-names>SN</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>JW</given-names></name><name name-style="western"><surname>Linder</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Tell</surname><given-names>RM</given-names></name><name name-style="western"><surname>Jenkins-Moore</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2 exposure in wild white-tailed deer (Odocoileus virginianus)</article-title><source>Proc Natl Acad Sci USA</source><year>2021</year><volume>118</volume><fpage>e2114828118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2114828118</pub-id><pub-id pub-id-type="pmid">34732584</pub-id><pub-id pub-id-type="pmcid">PMC8617405</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>ZG</given-names></name><etal/></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>265</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmid">32015508</pub-id><pub-id pub-id-type="pmcid">PMC7094943</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>The spike protein of SARS-CoV&#8212;a target for vaccine and therapeutic development</article-title><source>Nat Rev Microbiol</source><year>2009</year><volume>7</volume><fpage>226</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2090</pub-id><pub-id pub-id-type="pmid">19198616</pub-id><pub-id pub-id-type="pmcid">PMC2750777</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bok</surname><given-names>K</given-names></name><name name-style="western"><surname>Sitar</surname><given-names>S</given-names></name><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></name></person-group><article-title>Accelerated COVID-19 vaccine development: milestones, lessons, and prospects</article-title><source>Immunity</source><year>2021</year><volume>54</volume><fpage>1636</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.07.017</pub-id><pub-id pub-id-type="pmid">34348117</pub-id><pub-id pub-id-type="pmcid">PMC8328682</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiolet</surname><given-names>T</given-names></name><name name-style="western"><surname>Kherabi</surname><given-names>Y</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ghosn</surname><given-names>J</given-names></name><name name-style="western"><surname>Peiffer-Smadja</surname><given-names>N</given-names></name></person-group><article-title>Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review</article-title><source>Clin Microbiol Infect</source><year>2022</year><volume>28</volume><fpage>202</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2021.10.005</pub-id><pub-id pub-id-type="pmid">34715347</pub-id><pub-id pub-id-type="pmcid">PMC8548286</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ssentongo</surname><given-names>P</given-names></name><name name-style="western"><surname>Ssentongo</surname><given-names>AE</given-names></name><name name-style="western"><surname>Voleti</surname><given-names>N</given-names></name><name name-style="western"><surname>Groff</surname><given-names>D</given-names></name><name name-style="western"><surname>Sun</surname><given-names>A</given-names></name><name name-style="western"><surname>Ba</surname><given-names>DM</given-names></name><etal/></person-group><article-title>SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis</article-title><source>BMC Infect Dis</source><year>2022</year><volume>22</volume><fpage>439</fpage><pub-id pub-id-type="doi">10.1186/s12879-022-07418-y</pub-id><pub-id pub-id-type="pmid">35525973</pub-id><pub-id pub-id-type="pmcid">PMC9077344</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R</given-names></name><etal/></person-group><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title><source>N Engl J Med</source><year>2020</year><volume>384</volume><fpage>403</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A</given-names></name><name name-style="western"><surname>C&#225;rdenas</surname><given-names>V</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G</given-names></name><name name-style="western"><surname>Grinsztejn</surname><given-names>B</given-names></name><etal/></person-group><article-title>Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><fpage>2187</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2101544</pub-id><pub-id pub-id-type="pmid">33882225</pub-id><pub-id pub-id-type="pmcid">PMC8220996</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardt</surname><given-names>K</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Le Gars</surname><given-names>M</given-names></name><name name-style="western"><surname>Truyers</surname><given-names>C</given-names></name><name name-style="western"><surname>Lowson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet Infect Dis</source><year>2022</year><volume>22</volume><fpage>1703</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00506-0</pub-id><pub-id pub-id-type="pmid">36113538</pub-id><pub-id pub-id-type="pmcid">PMC9639796</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suah</surname><given-names>JL</given-names></name><name name-style="western"><surname>Tng</surname><given-names>BH</given-names></name><name name-style="western"><surname>Tok</surname><given-names>P</given-names></name><name name-style="western"><surname>Husin</surname><given-names>M</given-names></name><name name-style="western"><surname>Thevananthan</surname><given-names>T</given-names></name><name name-style="western"><surname>Peariasamy</surname><given-names>KM</given-names></name><name name-style="western"><surname>Sivasampu</surname><given-names>S</given-names></name></person-group><article-title>Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection</article-title><source>Emerg Microbes Infect</source><year>2022</year><volume>11</volume><fpage>1343</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1080/22221751.2022.2072773</pub-id><pub-id pub-id-type="pmid">35499301</pub-id><pub-id pub-id-type="pmcid">PMC9132393</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>N</given-names></name><name name-style="western"><surname>Stowe</surname><given-names>J</given-names></name><name name-style="western"><surname>Kirsebom</surname><given-names>F</given-names></name><name name-style="western"><surname>Toffa</surname><given-names>S</given-names></name><name name-style="western"><surname>Rickeard</surname><given-names>T</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>E</given-names></name><etal/></person-group><article-title>Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant</article-title><source>N Engl J Med</source><year>2022</year><volume>386</volume><fpage>1532</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2119451</pub-id><pub-id pub-id-type="pmid">35249272</pub-id><pub-id pub-id-type="pmcid">PMC8908811</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Md Yusof</surname><given-names>MY</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>J</given-names></name><name name-style="western"><surname>Saleem</surname><given-names>B</given-names></name><name name-style="western"><surname>Vandevelde</surname><given-names>C</given-names></name><name name-style="western"><surname>Dass</surname><given-names>S</given-names></name><name name-style="western"><surname>Savic</surname><given-names>S</given-names></name><etal/></person-group><article-title>Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study</article-title><source>Lancet Rheumatol</source><year>2023</year><volume>5</volume><fpage>e88</fpage><lpage>e98</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(23)00004-8</pub-id><pub-id pub-id-type="pmid">36712951</pub-id><pub-id pub-id-type="pmcid">PMC9873269</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ponsford</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Shillitoe</surname><given-names>BMJ</given-names></name><name name-style="western"><surname>Humphreys</surname><given-names>IR</given-names></name><name name-style="western"><surname>Gennery</surname><given-names>AR</given-names></name><name name-style="western"><surname>Jolles</surname><given-names>S</given-names></name></person-group><article-title>COVID-19 and X-linked agammaglobulinemia (XLA)&#8212;insights from a monogenic antibody deficiency</article-title><source>Curr Opin Allergy Clin Immunol</source><year>2021</year><volume>21</volume><fpage>525</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1097/ACI.0000000000000792</pub-id><pub-id pub-id-type="pmid">34596095</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menegale</surname><given-names>F</given-names></name><name name-style="western"><surname>Manica</surname><given-names>M</given-names></name><name name-style="western"><surname>Zardini</surname><given-names>A</given-names></name><name name-style="western"><surname>Guzzetta</surname><given-names>G</given-names></name><name name-style="western"><surname>Marziano</surname><given-names>V</given-names></name><name name-style="western"><surname>d'Andrea</surname><given-names>V</given-names></name><etal/></person-group><article-title>Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis</article-title><source>JAMA Netw Open</source><year>2023</year><volume>6</volume><fpage>e2310650</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.10650</pub-id><pub-id pub-id-type="pmid">37133863</pub-id><pub-id pub-id-type="pmcid">PMC10157431</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohn</surname><given-names>BA</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>PM</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>CC</given-names></name><name name-style="western"><surname>Krigbaum</surname><given-names>NY</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>AW</given-names></name></person-group><article-title>SARS-CoV-2 vaccine protection and deaths among US veterans during 2021</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>331</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1126/science.abm0620</pub-id><pub-id pub-id-type="pmid">34735261</pub-id><pub-id pub-id-type="pmcid">PMC9836205</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tenforde</surname><given-names>MW</given-names></name><name name-style="western"><surname>Self</surname><given-names>WH</given-names></name><name name-style="western"><surname>Adams</surname><given-names>K</given-names></name><name name-style="western"><surname>Gaglani</surname><given-names>M</given-names></name><name name-style="western"><surname>Ginde</surname><given-names>AA</given-names></name><name name-style="western"><surname>McNeal</surname><given-names>T</given-names></name><etal/></person-group><article-title>Association between mRNA vaccination and COVID-19 hospitalization and disease severity</article-title><source>JAMA</source><year>2021</year><volume>326</volume><fpage>2043</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.19499</pub-id><pub-id pub-id-type="pmid">34734975</pub-id><pub-id pub-id-type="pmcid">PMC8569602</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cele</surname><given-names>S</given-names></name><name name-style="western"><surname>Gazy</surname><given-names>I</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>L</given-names></name><name name-style="western"><surname>Hwa</surname><given-names>SH</given-names></name><name name-style="western"><surname>Tegally</surname><given-names>H</given-names></name><name name-style="western"><surname>Lustig</surname><given-names>G</given-names></name><etal/></person-group><article-title>Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma</article-title><source>Nature</source><year>2021</year><volume>593</volume><fpage>142</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03471-w</pub-id><pub-id pub-id-type="pmid">33780970</pub-id><pub-id pub-id-type="pmcid">PMC9867906</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitragotri</surname><given-names>S</given-names></name></person-group><article-title>Immunization without needles</article-title><source>Nat Rev Immunol</source><year>2005</year><volume>5</volume><fpage>905</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/nri1728</pub-id><pub-id pub-id-type="pmid">16239901</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diniz</surname><given-names>MO</given-names></name><name name-style="western"><surname>Maini</surname><given-names>MK</given-names></name><name name-style="western"><surname>Swadling</surname><given-names>L</given-names></name></person-group><article-title>T cell control of SARS-CoV-2: when, which, and where?</article-title><source>Semin Immunol</source><year>2023</year><volume>70</volume><fpage>101828</fpage><pub-id pub-id-type="doi">10.1016/j.smim.2023.101828</pub-id><pub-id pub-id-type="pmid">37651850</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allie</surname><given-names>SR</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>JE</given-names></name><name name-style="western"><surname>Mudunuru</surname><given-names>U</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>MD</given-names></name><name name-style="western"><surname>Graf</surname><given-names>BA</given-names></name><name name-style="western"><surname>Lund</surname><given-names>FE</given-names></name><name name-style="western"><surname>Randall</surname><given-names>TD</given-names></name></person-group><article-title>The establishment of resident memory B cells in the lung requires local antigen encounter</article-title><source>Nat Immunol</source><year>2019</year><volume>20</volume><fpage>97</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0260-6</pub-id><pub-id pub-id-type="pmid">30510223</pub-id><pub-id pub-id-type="pmcid">PMC6392030</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>C</given-names></name><name name-style="western"><surname>Cox</surname><given-names>TM</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Son</surname><given-names>YM</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>IS</given-names></name><etal/></person-group><article-title>Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination</article-title><source>Sci Immunol</source><year>2022</year><volume>7</volume><fpage>eadd4853</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.add4853</pub-id><pub-id pub-id-type="pmid">35857583</pub-id><pub-id pub-id-type="pmcid">PMC9348751</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Mangalam</surname><given-names>AK</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses</article-title><source>Immunity</source><year>2016</year><volume>44</volume><fpage>1379</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.006</pub-id><pub-id pub-id-type="pmid">27287409</pub-id><pub-id pub-id-type="pmcid">PMC4917442</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabo</surname><given-names>PA</given-names></name><name name-style="western"><surname>Dogra</surname><given-names>P</given-names></name><name name-style="western"><surname>Gray</surname><given-names>JI</given-names></name><name name-style="western"><surname>Wells</surname><given-names>SB</given-names></name><name name-style="western"><surname>Connors</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Weisberg</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19</article-title><source>Immunity</source><year>2021</year><volume>54</volume><fpage>797</fpage><lpage>814.e796</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.03.005</pub-id><pub-id pub-id-type="pmid">33765436</pub-id><pub-id pub-id-type="pmcid">PMC7951561</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><fpage>842</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0901-9</pub-id><pub-id pub-id-type="pmid">32398875</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitsi</surname><given-names>E</given-names></name><name name-style="western"><surname>Diniz</surname><given-names>MO</given-names></name><name name-style="western"><surname>Rein&#233;</surname><given-names>J</given-names></name><name name-style="western"><surname>Collins</surname><given-names>AM</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>RE</given-names></name><name name-style="western"><surname>Hyder-Wright</surname><given-names>A</given-names></name><etal/></person-group><article-title>Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>6815</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-42433-w</pub-id><pub-id pub-id-type="pmid">37884506</pub-id><pub-id pub-id-type="pmcid">PMC10603102</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diniz</surname><given-names>MO</given-names></name><name name-style="western"><surname>Mitsi</surname><given-names>E</given-names></name><name name-style="western"><surname>Swadling</surname><given-names>L</given-names></name><name name-style="western"><surname>Rylance</surname><given-names>J</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M</given-names></name><name name-style="western"><surname>Goldblatt</surname><given-names>D</given-names></name><etal/></person-group><article-title>Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2</article-title><source>Nat Immunol</source><year>2022</year><volume>23</volume><fpage>1324</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01292-1</pub-id><pub-id pub-id-type="pmid">36038709</pub-id><pub-id pub-id-type="pmcid">PMC9477726</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niessl</surname><given-names>J</given-names></name><name name-style="western"><surname>Sekine</surname><given-names>T</given-names></name><name name-style="western"><surname>Lange</surname><given-names>J</given-names></name><name name-style="western"><surname>Konya</surname><given-names>V</given-names></name><name name-style="western"><surname>Forkel</surname><given-names>M</given-names></name><name name-style="western"><surname>Maric</surname><given-names>J</given-names></name><etal/></person-group><article-title>Identification of resident memory CD8(+) T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue</article-title><source>Sci Immunol</source><year>2021</year><volume>6</volume><fpage>eabk0894</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abk0894</pub-id><pub-id pub-id-type="pmid">34519539</pub-id><pub-id pub-id-type="pmcid">PMC10763663</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chalkias</surname><given-names>S</given-names></name><name name-style="western"><surname>Harper</surname><given-names>C</given-names></name><name name-style="western"><surname>Vrbicky</surname><given-names>K</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>SR</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B</given-names></name><name name-style="western"><surname>Brosz</surname><given-names>A</given-names></name><etal/></person-group><article-title>A bivalent omicron-containing booster vaccine against Covid-19</article-title><source>N Engl J Med</source><year>2022</year><volume>387</volume><fpage>1279</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2208343</pub-id><pub-id pub-id-type="pmid">36112399</pub-id><pub-id pub-id-type="pmcid">PMC9511634</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis-Gardner</surname><given-names>ME</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L</given-names></name><name name-style="western"><surname>Wali</surname><given-names>B</given-names></name><name name-style="western"><surname>Samaha</surname><given-names>H</given-names></name><name name-style="western"><surname>Solis</surname><given-names>D</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M</given-names></name><etal/></person-group><article-title>Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster</article-title><source>N Engl J Med</source><year>2022</year><volume>388</volume><fpage>183</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2214293</pub-id><pub-id pub-id-type="pmid">36546661</pub-id><pub-id pub-id-type="pmcid">PMC9812288</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Branche</surname><given-names>AR</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></name><name name-style="western"><surname>Diemert</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name><name name-style="western"><surname>Losada</surname><given-names>C</given-names></name><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial</article-title><source>Nat Med</source><year>2023</year><volume>29</volume><fpage>2334</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02503-4</pub-id><pub-id pub-id-type="pmid">37640860</pub-id><pub-id pub-id-type="pmcid">PMC10504073</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Pade</surname><given-names>C</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>JM</given-names></name><name name-style="western"><surname>Otter</surname><given-names>AD</given-names></name><name name-style="western"><surname>Lin</surname><given-names>KM</given-names></name><name name-style="western"><surname>Mu&#241;oz Sandoval</surname><given-names>D</given-names></name><etal/></person-group><article-title>Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure</article-title><source>Science</source><year>2022</year><volume>377</volume><fpage>eabq1841</fpage><pub-id pub-id-type="doi">10.1126/science.abq1841</pub-id><pub-id pub-id-type="pmid">35699621</pub-id><pub-id pub-id-type="pmcid">PMC9210451</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atyeo</surname><given-names>C</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S</given-names></name><name name-style="western"><surname>Zohar</surname><given-names>T</given-names></name><name name-style="western"><surname>Slein</surname><given-names>MD</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J</given-names></name><name name-style="western"><surname>Loos</surname><given-names>C</given-names></name><etal/></person-group><article-title>Distinct early serological signatures track with SARS-CoV-2 survival</article-title><source>Immunity</source><year>2020</year><volume>53</volume><fpage>524</fpage><lpage>32.e524</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.07.020</pub-id><pub-id pub-id-type="pmid">32783920</pub-id><pub-id pub-id-type="pmcid">PMC7392190</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N</given-names></name><name name-style="western"><surname>Guebre-Xabier</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>AL</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C</given-names></name><name name-style="western"><surname>Pullen</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination</article-title><source>Cell Rep Med</source><year>2021</year><volume>2</volume><fpage>100405</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100405</pub-id><pub-id pub-id-type="pmid">34485950</pub-id><pub-id pub-id-type="pmcid">PMC8405506</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplonek</surname><given-names>P</given-names></name><name name-style="western"><surname>Cizmeci</surname><given-names>D</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S</given-names></name><name name-style="western"><surname>Collier</surname><given-names>AR</given-names></name><name name-style="western"><surname>Suscovich</surname><given-names>T</given-names></name><name name-style="western"><surname>Linde</surname><given-names>C</given-names></name><etal/></person-group><article-title>mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions</article-title><source>Sci Transl Med</source><year>2022</year><volume>14</volume><fpage>eabm2311</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abm2311</pub-id><pub-id pub-id-type="pmid">35348368</pub-id><pub-id pub-id-type="pmcid">PMC8995030</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fielding</surname><given-names>CA</given-names></name><name name-style="western"><surname>Sabberwal</surname><given-names>P</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>JC</given-names></name><name name-style="western"><surname>Greenwood</surname><given-names>E</given-names></name><name name-style="western"><surname>Crozier</surname><given-names>T</given-names></name><name name-style="western"><surname>Zelek</surname><given-names>W</given-names></name><etal/></person-group><article-title>SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies</article-title><source>eLife</source><year>2022</year><volume>11</volume><fpage>e74489</fpage><pub-id pub-id-type="doi">10.7554/eLife.74489</pub-id><pub-id pub-id-type="pmid">35587364</pub-id><pub-id pub-id-type="pmcid">PMC9239683</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Provine</surname><given-names>NM</given-names></name><name name-style="western"><surname>Amini</surname><given-names>A</given-names></name><name name-style="western"><surname>Garner</surname><given-names>LC</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Dold</surname><given-names>C</given-names></name><name name-style="western"><surname>Hutchings</surname><given-names>C</given-names></name><etal/></person-group><article-title>MAIT cell activation augments adenovirus vector vaccine immunogenicity</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>521</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1126/science.aax8819</pub-id><pub-id pub-id-type="pmid">33510029</pub-id><pub-id pub-id-type="pmcid">PMC7610941</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flament</surname><given-names>H</given-names></name><name name-style="western"><surname>Rouland</surname><given-names>M</given-names></name><name name-style="western"><surname>Beaudoin</surname><given-names>L</given-names></name><name name-style="western"><surname>Toubal</surname><given-names>A</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>L</given-names></name><name name-style="western"><surname>Lebourgeois</surname><given-names>S</given-names></name><etal/></person-group><article-title>Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity</article-title><source>Nat Immunol</source><year>2021</year><volume>22</volume><fpage>322</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00870-z</pub-id><pub-id pub-id-type="pmid">33531712</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swadling</surname><given-names>L</given-names></name><name name-style="western"><surname>Diniz</surname><given-names>MO</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>NM</given-names></name><name name-style="western"><surname>Amin</surname><given-names>OE</given-names></name><name name-style="western"><surname>Chandran</surname><given-names>A</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>E</given-names></name><etal/></person-group><article-title>Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2</article-title><source>Nature</source><year>2022</year><volume>601</volume><fpage>110</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04186-8</pub-id><pub-id pub-id-type="pmid">34758478</pub-id><pub-id pub-id-type="pmcid">PMC8732273</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>R</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Samanovic</surname><given-names>MI</given-names></name><name name-style="western"><surname>Herati</surname><given-names>RS</given-names></name><name name-style="western"><surname>Blair</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Multimodal single-cell datasets characterize antigen-specific CD8+ T cells across SARS-CoV-2 vaccination and infection</article-title><source>Nat Immunol</source><year>2023</year><volume>24</volume><fpage>1725</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01608-9</pub-id><pub-id pub-id-type="pmid">37735591</pub-id><pub-id pub-id-type="pmcid">PMC10522491</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Painter</surname><given-names>MM</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>TS</given-names></name><name name-style="western"><surname>Lundgreen</surname><given-names>KA</given-names></name><name name-style="western"><surname>Santos</surname><given-names>J</given-names></name><name name-style="western"><surname>Qin</surname><given-names>JS</given-names></name><name name-style="western"><surname>Goel</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection</article-title><source>Nat Immunol</source><year>2023</year><volume>24</volume><fpage>1711</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01613-y</pub-id><pub-id pub-id-type="pmid">37735592</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scurr</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lippiatt</surname><given-names>G</given-names></name><name name-style="western"><surname>Capitani</surname><given-names>L</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>K</given-names></name><name name-style="western"><surname>Lauder</surname><given-names>SN</given-names></name><name name-style="western"><surname>Smart</surname><given-names>K</given-names></name><etal/></person-group><article-title>Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>5422</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-32985-8</pub-id><pub-id pub-id-type="pmid">36130936</pub-id><pub-id pub-id-type="pmcid">PMC9492763</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandran</surname><given-names>A</given-names></name><name name-style="western"><surname>Rosenheim</surname><given-names>J</given-names></name><name name-style="western"><surname>Nageswaran</surname><given-names>G</given-names></name><name name-style="western"><surname>Swadling</surname><given-names>L</given-names></name><name name-style="western"><surname>Pollara</surname><given-names>G</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections</article-title><source>Cell Rep Med</source><year>2022</year><volume>3</volume><fpage>100557</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100557</pub-id><pub-id pub-id-type="pmid">35474751</pub-id><pub-id pub-id-type="pmcid">PMC8895494</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swadling</surname><given-names>L</given-names></name><name name-style="western"><surname>Maini</surname><given-names>MK</given-names></name><name name-style="western"><surname>Can</surname><given-names>T</given-names></name></person-group><article-title>Cells abort SARS-CoV-2 and other viral infections?</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>4371</fpage><pub-id pub-id-type="doi">10.3390/ijms24054371</pub-id><pub-id pub-id-type="pmid">36901802</pub-id><pub-id pub-id-type="pmcid">PMC10002440</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loyal</surname><given-names>L</given-names></name><name name-style="western"><surname>Braun</surname><given-names>J</given-names></name><name name-style="western"><surname>Henze</surname><given-names>L</given-names></name><name name-style="western"><surname>Kruse</surname><given-names>B</given-names></name><name name-style="western"><surname>Dingeldey</surname><given-names>M</given-names></name><name name-style="western"><surname>Reimer</surname><given-names>U</given-names></name><etal/></person-group><article-title>Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses upon infection and vaccination</article-title><source>Science</source><year>2021</year><volume>374</volume><fpage>eabh1823</fpage><pub-id pub-id-type="doi">10.1126/science.abh1823</pub-id><pub-id pub-id-type="pmid">34465633</pub-id><pub-id pub-id-type="pmcid">PMC10026850</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinto</surname><given-names>D</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>MM</given-names></name><name name-style="western"><surname>Czudnochowski</surname><given-names>N</given-names></name><name name-style="western"><surname>Low</surname><given-names>JS</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>MA</given-names></name><name name-style="western"><surname>Housley</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Broad betacoronavirus neutralization by a stem helix-specific human antibody</article-title><source>Science</source><year>2021</year><volume>373</volume><fpage>1109</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1126/science.abj3321</pub-id><pub-id pub-id-type="pmid">34344823</pub-id><pub-id pub-id-type="pmcid">PMC9268357</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><mixed-citation publication-type="other">Addetia A, Park YJ, Starr T, Greaney AJ, Sprouse KR, Bowen JE, et al. Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail. bioRxiv. 2022.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2023.112621</pub-id><pub-id pub-id-type="pmcid">PMC10213294</pub-id><pub-id pub-id-type="pmid">37300832</pub-id></mixed-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>KW</given-names></name><name name-style="western"><surname>Faulkner</surname><given-names>N</given-names></name><name name-style="western"><surname>Cornish</surname><given-names>GH</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>A</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>R</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>S</given-names></name><etal/></person-group><article-title>Preexisting and de novo humoral immunity to SARS-CoV-2 in humans</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>1339</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1126/science.abe1107</pub-id><pub-id pub-id-type="pmid">33159009</pub-id><pub-id pub-id-type="pmcid">PMC7857411</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>LE</given-names></name><name name-style="western"><surname>Leist</surname><given-names>SR</given-names></name><name name-style="western"><surname>Dinnon</surname><given-names>KH</given-names></name><name name-style="western"><surname>West</surname><given-names>A</given-names></name><name name-style="western"><surname>Gully</surname><given-names>KL</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination</article-title><source>Cell Rep</source><year>2023</year><volume>42</volume><fpage>112326</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112326</pub-id><pub-id pub-id-type="pmid">37000623</pub-id><pub-id pub-id-type="pmcid">PMC10063157</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>KW</given-names></name><name name-style="western"><surname>Faulkner</surname><given-names>N</given-names></name><name name-style="western"><surname>Finsterbusch</surname><given-names>K</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>R</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>S</given-names></name><etal/></person-group><article-title>SARS-CoV-2 S2&#8211;targeted vaccination elicits broadly neutralizing antibodies</article-title><source>Sci Transl Med</source><year>2022</year><volume>14</volume><fpage>eabn3715</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abn3715</pub-id><pub-id pub-id-type="pmid">35895836</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Yi</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2</article-title><source>Nat Microbiol</source><year>2022</year><volume>7</volume><fpage>1063</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01155-3</pub-id><pub-id pub-id-type="pmid">35773398</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poh</surname><given-names>CM</given-names></name><name name-style="western"><surname>Carissimo</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Amrun</surname><given-names>SN</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CY</given-names></name><name name-style="western"><surname>Chee</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients</article-title><source>Nat Comm</source><year>2020</year><volume>11</volume><fpage>2806</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16638-2</pub-id><pub-id pub-id-type="pmcid">PMC7264175</pub-id><pub-id pub-id-type="pmid">32483236</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Low</surname><given-names>JS</given-names></name><name name-style="western"><surname>Jerak</surname><given-names>J</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>MA</given-names></name><name name-style="western"><surname>McCallum</surname><given-names>M</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>D</given-names></name><name name-style="western"><surname>Cassotta</surname><given-names>A</given-names></name><etal/></person-group><article-title>ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies</article-title><source>Science</source><year>2022</year><volume>377</volume><fpage>735</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1126/science.abq2679</pub-id><pub-id pub-id-type="pmid">35857703</pub-id><pub-id pub-id-type="pmcid">PMC9348755</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ozorowski</surname><given-names>G</given-names></name><name name-style="western"><surname>Andreano</surname><given-names>E</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Copps</surname><given-names>J</given-names></name><name name-style="western"><surname>Piccini</surname><given-names>G</given-names></name><etal/></person-group><article-title>Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody</article-title><source>Proc Natl Acad Sci USA</source><year>2022</year><volume>119</volume><fpage>e2120976119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2120976119</pub-id><pub-id pub-id-type="pmid">35549549</pub-id><pub-id pub-id-type="pmcid">PMC9171815</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F</given-names></name><name name-style="western"><surname>Yue</surname><given-names>S</given-names></name><etal/></person-group><article-title>A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD</article-title><source>Signal Transduct Target Ther</source><year>2022</year><volume>7</volume><fpage>114</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-00954-8</pub-id><pub-id pub-id-type="pmid">35383141</pub-id><pub-id pub-id-type="pmcid">PMC8980211</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jo</surname><given-names>WK</given-names></name><name name-style="western"><surname>Drosten</surname><given-names>C</given-names></name><name name-style="western"><surname>Drexler</surname><given-names>JF</given-names></name></person-group><article-title>The evolutionary dynamics of endemic human coronaviruses</article-title><source>Virus Evol</source><year>2021</year><volume>7</volume><fpage>020</fpage><pub-id pub-id-type="doi">10.1093/ve/veab020</pub-id><pub-id pub-id-type="pmcid">PMC7980080</pub-id><pub-id pub-id-type="pmid">33768964</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eguia</surname><given-names>RT</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>K</given-names></name><name name-style="western"><surname>Stevens-Ayers</surname><given-names>T</given-names></name><name name-style="western"><surname>Kelnhofer-Millevolte</surname><given-names>L</given-names></name><name name-style="western"><surname>Greninger</surname><given-names>AL</given-names></name><name name-style="western"><surname>Englund</surname><given-names>JA</given-names></name><etal/></person-group><article-title>A human coronavirus evolves antigenically to escape antibody immunity</article-title><source>PLOS Pathog</source><year>2021</year><volume>17</volume><fpage>e1009453</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1009453</pub-id><pub-id pub-id-type="pmid">33831132</pub-id><pub-id pub-id-type="pmcid">PMC8031418</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chia</surname><given-names>WN</given-names></name><name name-style="western"><surname>Tan</surname><given-names>CW</given-names></name><name name-style="western"><surname>Tan</surname><given-names>A</given-names></name><name name-style="western"><surname>Young</surname><given-names>B</given-names></name><name name-style="western"><surname>Starr</surname><given-names>TN</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>E</given-names></name><etal/></person-group><article-title>Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor</article-title><source>Sci Adv</source><year>2023</year><volume>9</volume><fpage>eade3470</fpage><pub-id pub-id-type="doi">10.1126/sciadv.ade3470</pub-id><pub-id pub-id-type="pmid">37494438</pub-id><pub-id pub-id-type="pmcid">PMC10371021</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sewell</surname><given-names>AK</given-names></name></person-group><article-title>Why must T cells be cross-reactive?</article-title><source>Nat Rev Immunol</source><year>2012</year><volume>12</volume><fpage>669</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/nri3279</pub-id><pub-id pub-id-type="pmid">22918468</pub-id><pub-id pub-id-type="pmcid">PMC7097784</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarke</surname><given-names>A</given-names></name><name name-style="western"><surname>Coelho</surname><given-names>CH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Yu</surname><given-names>ED</given-names></name><name name-style="western"><surname>Methot</surname><given-names>N</given-names></name><etal/></person-group><article-title>SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>847</fpage><lpage>59.e811</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.015</pub-id><pub-id pub-id-type="pmid">35139340</pub-id><pub-id pub-id-type="pmcid">PMC8784649</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keeton</surname><given-names>R</given-names></name><name name-style="western"><surname>Tincho</surname><given-names>MB</given-names></name><name name-style="western"><surname>Ngomti</surname><given-names>A</given-names></name><name name-style="western"><surname>Baguma</surname><given-names>R</given-names></name><name name-style="western"><surname>Benede</surname><given-names>N</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>A</given-names></name><etal/></person-group><article-title>T cell responses to SARS-CoV-2 spike cross-recognize Omicron</article-title><source>Nature</source><year>2022</year><volume>603</volume><fpage>488</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04460-3</pub-id><pub-id pub-id-type="pmid">35102311</pub-id><pub-id pub-id-type="pmcid">PMC8930768</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C</given-names></name><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>TR</given-names></name><name name-style="western"><surname>Niessl</surname><given-names>J</given-names></name><name name-style="western"><surname>Olofsson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>472</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01700-x</pub-id><pub-id pub-id-type="pmid">35042228</pub-id><pub-id pub-id-type="pmcid">PMC8938268</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolton</surname><given-names>G</given-names></name><name name-style="western"><surname>Rius</surname><given-names>C</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>MS</given-names></name><name name-style="western"><surname>Wall</surname><given-names>A</given-names></name><name name-style="western"><surname>Szomolay</surname><given-names>B</given-names></name><name name-style="western"><surname>Behiry</surname><given-names>E</given-names></name><etal/></person-group><article-title>Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>2936</fpage><lpage>51.e2919</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.07.002</pub-id><pub-id pub-id-type="pmid">35931021</pub-id><pub-id pub-id-type="pmcid">PMC9279490</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Silva</surname><given-names>TI</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Lindsey</surname><given-names>BB</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D</given-names></name><name name-style="western"><surname>Moore</surname><given-names>SC</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>NS</given-names></name><etal/></person-group><article-title>The impact of viral mutations on recognition by SARS-CoV-2 specific T cells</article-title><source>iScience</source><year>2021</year><volume>24</volume><fpage>103353</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2021.103353</pub-id><pub-id pub-id-type="pmid">34729465</pub-id><pub-id pub-id-type="pmcid">PMC8552693</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelde</surname><given-names>A</given-names></name><name name-style="western"><surname>Bilich</surname><given-names>T</given-names></name><name name-style="western"><surname>Heitmann</surname><given-names>JS</given-names></name><name name-style="western"><surname>Maringer</surname><given-names>Y</given-names></name><name name-style="western"><surname>Salih</surname><given-names>HR</given-names></name><name name-style="western"><surname>Roerden</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition</article-title><source>Nat Immunol</source><year>2021</year><volume>22</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-00808-x</pub-id><pub-id pub-id-type="pmid">32999467</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mateus</surname><given-names>J</given-names></name><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Tarke</surname><given-names>A</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>SI</given-names></name><name name-style="western"><surname>Dan</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1126/science.abd3871</pub-id><pub-id pub-id-type="pmid">32753554</pub-id><pub-id pub-id-type="pmcid">PMC7574914</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>J</given-names></name><name name-style="western"><surname>Loyal</surname><given-names>L</given-names></name><name name-style="western"><surname>Frentsch</surname><given-names>M</given-names></name><name name-style="western"><surname>Wendisch</surname><given-names>D</given-names></name><name name-style="western"><surname>Georg</surname><given-names>P</given-names></name><name name-style="western"><surname>Kurth</surname><given-names>F</given-names></name><etal/></person-group><article-title>SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19</article-title><source>Nature</source><year>2020</year><volume>587</volume><fpage>270</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2598-9</pub-id><pub-id pub-id-type="pmid">32726801</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulien</surname><given-names>I</given-names></name><name name-style="western"><surname>Kemming</surname><given-names>J</given-names></name><name name-style="western"><surname>Oberhardt</surname><given-names>V</given-names></name><name name-style="western"><surname>Wild</surname><given-names>K</given-names></name><name name-style="western"><surname>Seidel</surname><given-names>LM</given-names></name><name name-style="western"><surname>Killmer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-01143-2</pub-id><pub-id pub-id-type="pmid">33184509</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Low</surname><given-names>JS</given-names></name><name name-style="western"><surname>Vaqueirinho</surname><given-names>D</given-names></name><name name-style="western"><surname>Mele</surname><given-names>F</given-names></name><name name-style="western"><surname>Foglierini</surname><given-names>M</given-names></name><name name-style="western"><surname>Jerak</surname><given-names>J</given-names></name><name name-style="western"><surname>Perotti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2</article-title><source>Science</source><year>2021</year><volume>372</volume><fpage>1336</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1126/science.abg8985</pub-id><pub-id pub-id-type="pmid">34006597</pub-id><pub-id pub-id-type="pmcid">PMC8168615</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kundu</surname><given-names>R</given-names></name><name name-style="western"><surname>Narean</surname><given-names>JS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Fenn</surname><given-names>J</given-names></name><name name-style="western"><surname>Pillay</surname><given-names>T</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>ND</given-names></name><etal/></person-group><article-title>Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>80</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-27674-x</pub-id><pub-id pub-id-type="pmid">35013199</pub-id><pub-id pub-id-type="pmcid">PMC8748880</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarke</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Methot</surname><given-names>N</given-names></name><name name-style="western"><surname>Narowski</surname><given-names>TM</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>E</given-names></name><name name-style="western"><surname>Mallal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Targets and cross-reactivity of human T cell recognition of common cold coronaviruses</article-title><source>Cell Rep Med</source><year>2023</year><volume>4</volume><fpage>101088</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101088</pub-id><pub-id pub-id-type="pmid">37295422</pub-id><pub-id pub-id-type="pmcid">PMC10242702</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pothast</surname><given-names>CR</given-names></name><name name-style="western"><surname>Dijkland</surname><given-names>RC</given-names></name><name name-style="western"><surname>Thaler</surname><given-names>M</given-names></name><name name-style="western"><surname>Hagedoorn</surname><given-names>RS</given-names></name><name name-style="western"><surname>Kester</surname><given-names>M</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>AK</given-names></name><etal/></person-group><article-title>SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells</article-title><source>eLife</source><year>2022</year><volume>11</volume><fpage>e82050</fpage><pub-id pub-id-type="doi">10.7554/eLife.82050</pub-id><pub-id pub-id-type="pmid">36408799</pub-id><pub-id pub-id-type="pmcid">PMC9822249</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>CCS</given-names></name><name name-style="western"><surname>Owen</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Tham</surname><given-names>C</given-names></name><name name-style="western"><surname>Bertoletti</surname><given-names>A</given-names></name><name name-style="western"><surname>van Dorp</surname><given-names>L</given-names></name><name name-style="western"><surname>Balloux</surname><given-names>F</given-names></name></person-group><article-title>Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses</article-title><source>Infect Genet Evol</source><year>2021</year><volume>95</volume><fpage>105075</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2021.105075</pub-id><pub-id pub-id-type="pmid">34509646</pub-id><pub-id pub-id-type="pmcid">PMC8428999</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaisawangwong</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>h</given-names></name><name name-style="western"><surname>Kouo</surname><given-names>t</given-names></name><name name-style="western"><surname>Salathe</surname><given-names>sf</given-names></name><name name-style="western"><surname>Isser</surname><given-names>A</given-names></name><name name-style="western"><surname>Bieler</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Cross-reactivity of SARS-CoV-2&#8211; and influenza A&#8211;specific T cells in individuals exposed to SARS-CoV-2</article-title><source>JCI Insight</source><year>2022</year><volume>7</volume><fpage>e158308</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.158308</pub-id><pub-id pub-id-type="pmid">36134660</pub-id><pub-id pub-id-type="pmcid">PMC9675569</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartolo</surname><given-names>L</given-names></name><name name-style="western"><surname>Afroz</surname><given-names>S</given-names></name><name name-style="western"><surname>Pan</surname><given-names>YG</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><name name-style="western"><surname>Williams</surname><given-names>L</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CF</given-names></name><etal/></person-group><article-title>SARS-CoV-2&#8211;specific T cells in unexposed adults display broad trafficking potential and cross-react with commensal antigens</article-title><source>Sci Immunol</source><year>2022</year><volume>7</volume><fpage>eabn3127</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abn3127</pub-id><pub-id pub-id-type="pmid">35857619</pub-id><pub-id pub-id-type="pmcid">PMC9348748</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Sidney</surname><given-names>J</given-names></name><name name-style="western"><surname>Vita</surname><given-names>R</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B</given-names></name><name name-style="western"><surname>Crotty</surname><given-names>S</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D</given-names></name><name name-style="western"><surname>Sette</surname><given-names>A</given-names></name></person-group><article-title>SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><fpage>1076</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2021.05.010</pub-id><pub-id pub-id-type="pmid">34237248</pub-id><pub-id pub-id-type="pmcid">PMC8139264</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prakash</surname><given-names>S</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R</given-names></name><name name-style="western"><surname>Coulon</surname><given-names>PG</given-names></name><name name-style="western"><surname>Dhanushkodi</surname><given-names>NR</given-names></name><name name-style="western"><surname>Chentoufi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Tifrea</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Genome-wide B Cell, CD4(+), and CD8(+) T cell epitopes that are highly conserved between human and animal coronaviruses, identified from SARS-CoV-2 as targets for preemptive pan-coronavirus vaccines</article-title><source>J Immunol</source><year>2021</year><volume>206</volume><fpage>2566</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2001438</pub-id><pub-id pub-id-type="pmid">33911008</pub-id><pub-id pub-id-type="pmcid">PMC8722450</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Swadling</surname><given-names>L</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pade</surname><given-names>C</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>MP</given-names></name><name name-style="western"><surname>Diniz</surname><given-names>MO</given-names></name><etal/></person-group><article-title>Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection</article-title><source>Sci Immunol</source><year>2020</year><volume>5</volume><fpage>eabf3698</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abf3698</pub-id><pub-id pub-id-type="pmid">33361161</pub-id><pub-id pub-id-type="pmcid">PMC8101131</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Treibel</surname><given-names>TA</given-names></name><name name-style="western"><surname>Manisty</surname><given-names>C</given-names></name><name name-style="western"><surname>Burton</surname><given-names>M</given-names></name><name name-style="western"><surname>McKnight</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Lambourne</surname><given-names>J</given-names></name><name name-style="western"><surname>Augusto</surname><given-names>JB</given-names></name><etal/></person-group><article-title>COVID-19: PCR screening of asymptomatic health-care workers at London hospital</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1608</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31100-4</pub-id><pub-id pub-id-type="pmid">32401714</pub-id><pub-id pub-id-type="pmcid">PMC7206444</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sagar</surname><given-names>M</given-names></name><name name-style="western"><surname>Reifler</surname><given-names>K</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>M</given-names></name><name name-style="western"><surname>Miller</surname><given-names>NS</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>P</given-names></name><name name-style="western"><surname>White</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Recent endemic coronavirus infection is associated with less-severe COVID-19</article-title><source>J Clin Investig</source><year>2021</year><volume>131</volume><fpage>e143380</fpage><pub-id pub-id-type="doi">10.1172/JCI143380</pub-id><pub-id pub-id-type="pmid">32997649</pub-id><pub-id pub-id-type="pmcid">PMC7773342</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><mixed-citation publication-type="other">Bean, DJ, Monroe J, Liang YM, Borberg E, Senussi Y, Swank Z, et al. Heterotypic responses against nsp12/nsp13 from prior SARS-CoV-2 infection associates with lower subsequent endemic coronavirus incidence. <italic toggle="yes">bioRxiv</italic>, 2023.2010.2023.563621 (2023).</mixed-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eser</surname><given-names>TM</given-names></name><name name-style="western"><surname>Baranov</surname><given-names>O</given-names></name><name name-style="western"><surname>Huth</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>M</given-names></name><name name-style="western"><surname>De&#225;k</surname><given-names>F</given-names></name><name name-style="western"><surname>Held</surname><given-names>K</given-names></name><etal/></person-group><article-title>Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>2952</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-38020-8</pub-id><pub-id pub-id-type="pmid">37225706</pub-id><pub-id pub-id-type="pmcid">PMC10209201</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallajosyula</surname><given-names>V</given-names></name><name name-style="western"><surname>Ganjavi</surname><given-names>C</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>S</given-names></name><name name-style="western"><surname>McSween</surname><given-names>AM</given-names></name><name name-style="western"><surname>Pavlovitch-Bedzyk</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Wilhelmy</surname><given-names>J</given-names></name><etal/></person-group><article-title>CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-19</article-title><source>Sci Immunol</source><year>2021</year><volume>6</volume><fpage>eabg5669</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abg5669</pub-id><pub-id pub-id-type="pmid">34210785</pub-id><pub-id pub-id-type="pmcid">PMC8975171</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Letko</surname><given-names>M</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>SN</given-names></name><name name-style="western"><surname>Olival</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Plowright</surname><given-names>RK</given-names></name><name name-style="western"><surname>Munster</surname><given-names>VJ</given-names></name></person-group><article-title>Bat-borne virus diversity, spillover and emergence</article-title><source>Nat Rev Microbiol</source><year>2020</year><volume>18</volume><fpage>461</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-0394-z</pub-id><pub-id pub-id-type="pmid">32528128</pub-id><pub-id pub-id-type="pmcid">PMC7289071</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>KB</given-names></name><name name-style="western"><surname>Goh</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Wong</surname><given-names>KT</given-names></name><name name-style="western"><surname>Kamarulzaman</surname><given-names>A</given-names></name><name name-style="western"><surname>Tan</surname><given-names>PS</given-names></name><name name-style="western"><surname>Ksiazek</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia</article-title><source>Lancet</source><year>1999</year><volume>354</volume><fpage>1257</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(99)04299-3</pub-id><pub-id pub-id-type="pmid">10520635</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bossart</surname><given-names>KN</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>KA</given-names></name><name name-style="western"><surname>Crameri</surname><given-names>G</given-names></name><name name-style="western"><surname>Dimitrov</surname><given-names>AS</given-names></name><name name-style="western"><surname>McEachern</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody</article-title><source>J Infect Dis</source><year>2008</year><volume>197</volume><fpage>846</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1086/528801</pub-id><pub-id pub-id-type="pmid">18271743</pub-id><pub-id pub-id-type="pmcid">PMC7199872</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middleton</surname><given-names>D</given-names></name><name name-style="western"><surname>Pallister</surname><given-names>J</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R</given-names></name><name name-style="western"><surname>Feng</surname><given-names>YR</given-names></name><name name-style="western"><surname>Haining</surname><given-names>J</given-names></name><name name-style="western"><surname>Arkinstall</surname><given-names>R</given-names></name><etal/></person-group><article-title>Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health</article-title><source>Emerg Infect Dis</source><year>2014</year><volume>20</volume><fpage>372</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.3201/eid2003.131159</pub-id><pub-id pub-id-type="pmid">24572697</pub-id><pub-id pub-id-type="pmcid">PMC3944873</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeltina</surname><given-names>A</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>TA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name></person-group><article-title>Emerging paramyxoviruses: receptor tropism and zoonotic potential</article-title><source>PLoS Pathog</source><year>2016</year><volume>12</volume><fpage>e1005390</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1005390</pub-id><pub-id pub-id-type="pmid">26915013</pub-id><pub-id pub-id-type="pmcid">PMC4767434</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nachbagauer</surname><given-names>R</given-names></name><name name-style="western"><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Is a universal influenza virus vaccine possible?</article-title><source>Annu Rev Med</source><year>2020</year><volume>71</volume><fpage>315</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-120617-041310</pub-id><pub-id pub-id-type="pmid">31600454</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>CW</given-names></name><name name-style="western"><surname>Valkenburg</surname><given-names>SA</given-names></name><name name-style="western"><surname>Poon</surname><given-names>LLM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L-F</given-names></name></person-group><article-title>Broad-spectrum pan-genus and pan-family virus vaccines</article-title><source>Cell Host Microbe</source><year>2023</year><volume>31</volume><fpage>902</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2023.05.017</pub-id><pub-id pub-id-type="pmid">37321173</pub-id><pub-id pub-id-type="pmcid">PMC10265776</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F</given-names></name><name name-style="western"><surname>Palese</surname><given-names>P</given-names></name></person-group><article-title>Influenza virus hemagglutinin stalk-based antibodies and vaccines</article-title><source>Curr Opin Virol</source><year>2013</year><volume>3</volume><fpage>521</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2013.07.007</pub-id><pub-id pub-id-type="pmid">23978327</pub-id><pub-id pub-id-type="pmcid">PMC3804342</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schotsaert</surname><given-names>M</given-names></name><name name-style="western"><surname>De Filette</surname><given-names>M</given-names></name><name name-style="western"><surname>Fiers</surname><given-names>W</given-names></name><name name-style="western"><surname>Saelens</surname><given-names>X</given-names></name></person-group><article-title>Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments</article-title><source>Expert Rev Vaccines</source><year>2009</year><volume>8</volume><fpage>499</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1586/erv.09.6</pub-id><pub-id pub-id-type="pmid">19348565</pub-id><pub-id pub-id-type="pmcid">PMC2706389</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koutsakos</surname><given-names>M</given-names></name><name name-style="western"><surname>Illing</surname><given-names>PT</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T</given-names></name><name name-style="western"><surname>Mifsud</surname><given-names>NA</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>JC</given-names></name><name name-style="western"><surname>Rizzetto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Human CD8+ T cell cross-reactivity across influenza A, B and C viruses</article-title><source>Nat Immunol</source><year>2019</year><volume>20</volume><fpage>613</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0320-6</pub-id><pub-id pub-id-type="pmid">30778243</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>RA</given-names></name><name name-style="western"><surname>Dube</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yates</surname><given-names>M</given-names></name><name name-style="western"><surname>Arnetorp</surname><given-names>S</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>E</given-names></name><etal/></person-group><article-title>Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study</article-title><source>Lancet Reg Health &#8211; Europe</source><year>2023</year><volume>35</volume><fpage>100747</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2023.100747</pub-id><pub-id pub-id-type="pmid">38115964</pub-id><pub-id pub-id-type="pmcid">PMC10730312</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><etal/></person-group><article-title>A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses</article-title><source>npj Vaccines</source><year>2023</year><volume>8</volume><fpage>132</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00728-5</pub-id><pub-id pub-id-type="pmid">37679361</pub-id><pub-id pub-id-type="pmcid">PMC10485063</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pleguezuelos</surname><given-names>O</given-names></name><name name-style="western"><surname>James</surname><given-names>E</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>A</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>V</given-names></name><name name-style="western"><surname>Rosas</surname><given-names>LA</given-names></name><name name-style="western"><surname>Cervantes-Medina</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study</article-title><source>NPJ Vaccines</source><year>2020</year><volume>5</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-0174-9</pub-id><pub-id pub-id-type="pmid">32194999</pub-id><pub-id pub-id-type="pmcid">PMC7069936</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castilla</surname><given-names>J</given-names></name><name name-style="western"><surname>Mart&#237;nez-Baz</surname><given-names>I</given-names></name><name name-style="western"><surname>Mart&#237;nez-Artola</surname><given-names>V</given-names></name><name name-style="western"><surname>Reina</surname><given-names>G</given-names></name><name name-style="western"><surname>Pozo</surname><given-names>F</given-names></name><name name-style="western"><surname>Garc&#237;a Cenoz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12</article-title><source>Euro Surveill</source><year>2013</year><volume>18</volume><fpage>20388</fpage><pub-id pub-id-type="pmid">23399423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/ese.18.05.20388-en</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Tsibane</surname><given-names>T</given-names></name><name name-style="western"><surname>McGraw</surname><given-names>PA</given-names></name><name name-style="western"><surname>House</surname><given-names>FS</given-names></name><name name-style="western"><surname>Keefer</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Hicar</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors</article-title><source>Nature</source><year>2008</year><volume>455</volume><fpage>532</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature07231</pub-id><pub-id pub-id-type="pmid">18716625</pub-id><pub-id pub-id-type="pmcid">PMC2848880</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Worobey</surname><given-names>M</given-names></name><name name-style="western"><surname>Han</surname><given-names>GZ</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A</given-names></name></person-group><article-title>Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus</article-title><source>Proc Natl Acad Sci USA</source><year>2014</year><volume>111</volume><fpage>8107</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1073/pnas.1324197111</pub-id><pub-id pub-id-type="pmid">24778238</pub-id><pub-id pub-id-type="pmcid">PMC4050607</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gostic</surname><given-names>KM</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>M</given-names></name><name name-style="western"><surname>Worobey</surname><given-names>M</given-names></name><name name-style="western"><surname>Lloyd-Smith</surname><given-names>JO</given-names></name></person-group><article-title>Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting</article-title><source>Science</source><year>2016</year><volume>354</volume><fpage>722</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1126/science.aag1322</pub-id><pub-id pub-id-type="pmid">27846599</pub-id><pub-id pub-id-type="pmcid">PMC5134739</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><mixed-citation publication-type="other">Edler P, Schwab LSU, Aban M, Wille M, Spirason N, Deng Y-M, et al. Differential cross-reactivity to the influenza B virus haemagglutinin underpins lineage-specific susceptibility between birth cohorts. 2023. <italic toggle="yes">bioRxiv</italic>, 2023.2008.2025.554879.</mixed-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Worobey</surname><given-names>M</given-names></name><name name-style="western"><surname>Plotkin</surname><given-names>S</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>SE</given-names></name></person-group><article-title>Influenza vaccines delivered in early childhood could turn antigenic sin into antigenic blessings</article-title><source>Cold Spring Harb Perspect Med</source><year>2020</year><volume>10</volume><fpage>a038471</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a038471</pub-id><pub-id pub-id-type="pmid">31964642</pub-id><pub-id pub-id-type="pmcid">PMC7371515</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><name name-style="western"><surname>Aderem</surname><given-names>A</given-names></name></person-group><article-title>A 2020 vision for vaccines against HIV, tuberculosis and malaria</article-title><source>Nature</source><year>2011</year><volume>473</volume><fpage>463</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nature10124</pub-id><pub-id pub-id-type="pmid">21614073</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vu</surname><given-names>MN</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>HG</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>AK</given-names></name></person-group><article-title>Current and future nanoparticle vaccines for COVID-19</article-title><source>eBioMedicine</source><year>2021</year><volume>74</volume><fpage>103699</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103699</pub-id><pub-id pub-id-type="pmid">34801965</pub-id><pub-id pub-id-type="pmcid">PMC8602808</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WH</given-names></name><name name-style="western"><surname>Sankhala</surname><given-names>RS</given-names></name><name name-style="western"><surname>Hajduczki</surname><given-names>A</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>PV</given-names></name><name name-style="western"><surname>Choe</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity</article-title><source>Cell Rep</source><year>2021</year><volume>37</volume><fpage>110143</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.110143</pub-id><pub-id pub-id-type="pmid">34919799</pub-id><pub-id pub-id-type="pmcid">PMC8651551</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrivastava</surname><given-names>S</given-names></name><name name-style="western"><surname>Carmen</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Basu</surname><given-names>S</given-names></name><name name-style="western"><surname>Sankhala</surname><given-names>RS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WH</given-names></name><etal/></person-group><article-title>SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies</article-title><source>npj Vaccines</source><year>2023</year><volume>8</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00638-6</pub-id><pub-id pub-id-type="pmid">36934088</pub-id><pub-id pub-id-type="pmcid">PMC10024299</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>PV</given-names></name><name name-style="western"><surname>Sciacca</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><etal/></person-group><article-title>Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques</article-title><source>Cell Rep Med</source><year>2023</year><volume>4</volume><fpage>101018</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101018</pub-id><pub-id pub-id-type="pmid">37023746</pub-id><pub-id pub-id-type="pmcid">PMC10040355</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunders</surname><given-names>KO</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E</given-names></name><name name-style="western"><surname>Parks</surname><given-names>R</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>DR</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses</article-title><source>Nature</source><year>2021</year><volume>594</volume><fpage>553</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03594-0</pub-id><pub-id pub-id-type="pmid">33971664</pub-id><pub-id pub-id-type="pmcid">PMC8528238</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>DR</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Barr</surname><given-names>M</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>6309</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-33985-4</pub-id><pub-id pub-id-type="pmid">36274085</pub-id><pub-id pub-id-type="pmcid">PMC9588772</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>DR</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>A</given-names></name><name name-style="western"><surname>Gavitt</surname><given-names>TD</given-names></name><name name-style="western"><surname>Mallory</surname><given-names>ML</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E</given-names></name><name name-style="western"><surname>Catanzaro</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice</article-title><source>Cell Reports</source><year>2023</year><volume>31</volume><fpage>113248</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.113248</pub-id><pub-id pub-id-type="pmcid">PMC10842144</pub-id><pub-id pub-id-type="pmid">37858337</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weidenbacher</surname><given-names>PA</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>M</given-names></name><name name-style="western"><surname>Friedland</surname><given-names>N</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>PS</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><etal/></person-group><article-title>A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>2149</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-37417-9</pub-id><pub-id pub-id-type="pmid">37069151</pub-id><pub-id pub-id-type="pmcid">PMC10110616</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><mixed-citation publication-type="other">Weidenbacher PA-B, Friedland N, Sanyal M, Morris MK, Do J, Hanson C, et al. Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concern. <italic toggle="yes">bioRxiv</italic>, 2023.2006.2027.546764 (2023).</mixed-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akache</surname><given-names>B</given-names></name><name name-style="western"><surname>Renner</surname><given-names>TM</given-names></name><name name-style="western"><surname>Tran</surname><given-names>A</given-names></name><name name-style="western"><surname>Deschatelets</surname><given-names>L</given-names></name><name name-style="western"><surname>Dudani</surname><given-names>R</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>21849</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-01363-7</pub-id><pub-id pub-id-type="pmid">34750472</pub-id><pub-id pub-id-type="pmcid">PMC8576046</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stark</surname><given-names>FC</given-names></name><name name-style="western"><surname>Akache</surname><given-names>B</given-names></name><name name-style="western"><surname>Deschatelets</surname><given-names>L</given-names></name><name name-style="western"><surname>Tran</surname><given-names>A</given-names></name><name name-style="western"><surname>Stuible</surname><given-names>M</given-names></name><name name-style="western"><surname>Durocher</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><fpage>9772</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-13819-5</pub-id><pub-id pub-id-type="pmid">35697917</pub-id><pub-id pub-id-type="pmcid">PMC9191540</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Felce</surname><given-names>SL</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D</given-names></name><name name-style="western"><surname>Penkava</surname><given-names>F</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X</given-names></name><etal/></person-group><article-title>An immunodominant NP105&#8211;113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease</article-title><source>Nat Immunol</source><year>2022</year><volume>23</volume><fpage>50</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01084-z</pub-id><pub-id pub-id-type="pmid">34853448</pub-id><pub-id pub-id-type="pmcid">PMC8709787</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Primard</surname><given-names>C</given-names></name><name name-style="western"><surname>Monch&#226;tre-Leroy</surname><given-names>E</given-names></name><name name-style="western"><surname>Del Campo</surname><given-names>J</given-names></name><name name-style="western"><surname>Valsesia</surname><given-names>S</given-names></name><name name-style="western"><surname>Nikly</surname><given-names>E</given-names></name><name name-style="western"><surname>Chevandier</surname><given-names>M</given-names></name><etal/></person-group><article-title>OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1188605</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1188605</pub-id><pub-id pub-id-type="pmid">37409116</pub-id><pub-id pub-id-type="pmcid">PMC10319154</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matchett</surname><given-names>WE</given-names></name><name name-style="western"><surname>Joag</surname><given-names>V</given-names></name><name name-style="western"><surname>Stolley</surname><given-names>JM</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>FK</given-names></name><name name-style="western"><surname>Quarnstrom</surname><given-names>CF</given-names></name><name name-style="western"><surname>Mickelson</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity</article-title><source>J Immunol</source><year>2021</year><volume>207</volume><fpage>376</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2100421</pub-id><pub-id pub-id-type="pmid">34193597</pub-id><pub-id pub-id-type="pmcid">PMC8516699</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>AA</given-names></name><name name-style="western"><surname>Gnanapragasam</surname><given-names>P</given-names></name><name name-style="western"><surname>Lee</surname><given-names>YE</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>PR</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S</given-names></name><name name-style="western"><surname>Kakutani</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>735</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1126/science.abf6840</pub-id><pub-id pub-id-type="pmid">33436524</pub-id><pub-id pub-id-type="pmcid">PMC7928838</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>AA</given-names></name><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name><name name-style="western"><surname>Greaney</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>H</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Starr</surname><given-names>TN</given-names></name><etal/></person-group><article-title>Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models</article-title><source>Science</source><year>2022</year><volume>377</volume><fpage>eabq0839</fpage><pub-id pub-id-type="doi">10.1126/science.abq0839</pub-id><pub-id pub-id-type="pmid">35857620</pub-id><pub-id pub-id-type="pmcid">PMC9273039</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>C</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AA</given-names></name><name name-style="western"><surname>Park</surname><given-names>M</given-names></name><name name-style="western"><surname>Hung</surname><given-names>AF</given-names></name><name name-style="western"><surname>Keeffe</surname><given-names>JR</given-names></name><name name-style="western"><surname>Gnanapragasam</surname><given-names>P</given-names></name><etal/></person-group><article-title>Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes</article-title><source>Immunity</source><year>2022</year><volume>55</volume><fpage>2419</fpage><lpage>2435.e2410</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2022.10.019</pub-id><pub-id pub-id-type="pmid">36370711</pub-id><pub-id pub-id-type="pmcid">PMC9606073</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><mixed-citation publication-type="other">Hills RA, Tan TK, Cohen AA, Keeffe JR, Keeble AH, Gnanapragasam PNP, et al. Multiviral quartet nanocages elicit broad anti-coronavirus responses for proactive vaccinology. <italic toggle="yes">bioRxiv</italic> (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-024-01655-9</pub-id><pub-id pub-id-type="pmcid">PMC11329374</pub-id><pub-id pub-id-type="pmid">38710880</pub-id></mixed-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name><name name-style="western"><surname>Fiala</surname><given-names>B</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A</given-names></name><name name-style="western"><surname>Wrenn</surname><given-names>S</given-names></name><name name-style="western"><surname>Pham</surname><given-names>MN</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>M</given-names></name><etal/></person-group><article-title>Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>1367</fpage><lpage>82.e1317</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.10.043</pub-id><pub-id pub-id-type="pmid">33160446</pub-id><pub-id pub-id-type="pmcid">PMC7604136</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>MC</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A</given-names></name><name name-style="western"><surname>Pham</surname><given-names>MN</given-names></name><name name-style="western"><surname>Greaney</surname><given-names>A</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>5432</fpage><lpage>47.e5416</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.09.015</pub-id><pub-id pub-id-type="pmid">34619077</pub-id><pub-id pub-id-type="pmcid">PMC8440233</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>M</given-names></name><name name-style="western"><surname>Powers</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><name name-style="western"><surname>Munt</surname><given-names>JE</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine</article-title><source>Sci Transl Med</source><year>2023</year><volume>15</volume><fpage>eadg7404</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adg7404</pub-id><pub-id pub-id-type="pmid">37163615</pub-id><pub-id pub-id-type="pmcid">PMC11032722</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><mixed-citation publication-type="other">Bozic J, Ahmed T, Ontsouka B, Fluckiger A-C, Diress A, Berthoud T, et al. Use of eVLP-based vaccine candidates to broaden immunity against SARS-CoV-2 variants. <italic toggle="yes">bioRxiv</italic>, 2021.2009.2028.462109 (2021).</mixed-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>L</given-names></name><name name-style="western"><surname>Renauer</surname><given-names>PA</given-names></name><name name-style="western"><surname>&#214;kten</surname><given-names>A</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Park</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><etal/></person-group><article-title>Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2</article-title><source>Cell Rep Med</source><year>2022</year><volume>3</volume><fpage>100634</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100634</pub-id><pub-id pub-id-type="pmid">35561673</pub-id><pub-id pub-id-type="pmcid">PMC9040489</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capone</surname><given-names>S</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A</given-names></name><name name-style="western"><surname>Hartnell</surname><given-names>F</given-names></name><name name-style="western"><surname>Sorbo</surname><given-names>MD</given-names></name><name name-style="western"><surname>Traboni</surname><given-names>C</given-names></name><name name-style="western"><surname>Vassilev</surname><given-names>V</given-names></name><etal/></person-group><article-title>Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans</article-title><source>npj Vaccines</source><year>2020</year><volume>5</volume><fpage>94</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-00240-0</pub-id><pub-id pub-id-type="pmid">33083029</pub-id><pub-id pub-id-type="pmcid">PMC7550607</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><mixed-citation publication-type="other">Prakash S, Dhanushkodi NR, Zayou L, Ibraim IC, Quadiri A, Coulon PG, et al. Cross-protection induced by highly conserved human B, CD4(+,) and CD8(+) T cell epitopes-based coronavirus vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern. <italic toggle="yes">bioRxiv</italic> (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1328905</pub-id><pub-id pub-id-type="pmcid">PMC10839970</pub-id><pub-id pub-id-type="pmid">38318166</pub-id></mixed-citation></ref><ref id="CR152"><label>152.</label><mixed-citation publication-type="other">Vishwanath S, Carnell GW, Ferrari M, Asbach B, Billmeier M, George C, et al. A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses. Nat Biomed Eng. 2023.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-023-01094-2</pub-id><pub-id pub-id-type="pmcid">PMC11839467</pub-id><pub-id pub-id-type="pmid">37749309</pub-id></mixed-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nathan</surname><given-names>A</given-names></name><name name-style="western"><surname>Rossin</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Kaseke</surname><given-names>C</given-names></name><name name-style="western"><surname>Park</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Khatri</surname><given-names>A</given-names></name><name name-style="western"><surname>Koundakjian</surname><given-names>D</given-names></name><etal/></person-group><article-title>Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>4401</fpage><lpage>13.e4410</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.06.029</pub-id><pub-id pub-id-type="pmid">34265281</pub-id><pub-id pub-id-type="pmcid">PMC8241654</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><mixed-citation publication-type="other">ValoTx. Valo therapeutics and immunoscape collaboration identifies immunogenic peptides to develop pan coronavirus vaccine. [Accessed 2023] Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.valotx.com/article/valo-therapeutics-and-immunoscape-collaboration-identifies-immunogenic-peptides-develop-pan">https://www.valotx.com/article/valo-therapeutics-and-immunoscape-collaboration-identifies-immunogenic-peptides-develop-pan</ext-link>. 2021.</mixed-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>AB</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>L</given-names></name><name name-style="western"><surname>Kinnear</surname><given-names>E</given-names></name><name name-style="western"><surname>Busse</surname><given-names>D</given-names></name><name name-style="western"><surname>Erbar</surname><given-names>S</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Self-amplifying RNA vaccines give equivalent protection against influenza to MRna vaccines but at much lower doses</article-title><source>Mol Ther</source><year>2018</year><volume>26</volume><fpage>446</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.11.017</pub-id><pub-id pub-id-type="pmid">29275847</pub-id><pub-id pub-id-type="pmcid">PMC5835025</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Alwis</surname><given-names>R</given-names></name><name name-style="western"><surname>Gan</surname><given-names>ES</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Leong</surname><given-names>YS</given-names></name><name name-style="western"><surname>Tan</surname><given-names>HC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>SL</given-names></name><etal/></person-group><article-title>A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice</article-title><source>Mol Ther</source><year>2021</year><volume>29</volume><fpage>1970</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.04.001</pub-id><pub-id pub-id-type="pmid">33823303</pub-id><pub-id pub-id-type="pmcid">PMC8019652</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappaport</surname><given-names>AR</given-names></name><name name-style="western"><surname>Hong</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Scallan</surname><given-names>CD</given-names></name><name name-style="western"><surname>Gitlin</surname><given-names>L</given-names></name><name name-style="western"><surname>Akoopie</surname><given-names>A</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>3289</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-31005-z</pub-id><pub-id pub-id-type="pmid">35672369</pub-id><pub-id pub-id-type="pmcid">PMC9173840</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>CD</given-names></name><name name-style="western"><surname>Scallan</surname><given-names>CD</given-names></name><name name-style="western"><surname>Kraemer Tardif</surname><given-names>LD</given-names></name><name name-style="western"><surname>Kachura</surname><given-names>MA</given-names></name><name name-style="western"><surname>Rappaport</surname><given-names>AR</given-names></name><name name-style="western"><surname>Koralek</surname><given-names>DO</given-names></name><etal/></person-group><article-title>GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for &#8805;6 months in previously-vaccinated older adults</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>3274</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-39053-9</pub-id><pub-id pub-id-type="pmid">37280238</pub-id><pub-id pub-id-type="pmcid">PMC10242235</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Teng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates</article-title><source>Proc Natl Acad Sci</source><year>2023</year><volume>120</volume><fpage>e2221713120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2221713120</pub-id><pub-id pub-id-type="pmid">36897979</pub-id><pub-id pub-id-type="pmcid">PMC10242718</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><etal/></person-group><article-title>A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs</article-title><source>Cell Res</source><year>2022</year><volume>32</volume><fpage>269</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1038/s41422-022-00612-2</pub-id><pub-id pub-id-type="pmid">35046518</pub-id><pub-id pub-id-type="pmcid">PMC8767042</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>CR</given-names></name><name name-style="western"><surname>Peachman</surname><given-names>KK</given-names></name><name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M</given-names></name><name name-style="western"><surname>Beck</surname><given-names>Z</given-names></name></person-group><article-title>Army liposome formulation (ALF) family of vaccine adjuvants</article-title><source>Expert Rev Vaccines</source><year>2020</year><volume>19</volume><fpage>279</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1080/14760584.2020.1745636</pub-id><pub-id pub-id-type="pmid">32228108</pub-id><pub-id pub-id-type="pmcid">PMC7412170</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmen</surname><given-names>JM</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>A</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>EB</given-names></name><name name-style="western"><surname>Sankhala</surname><given-names>RS</given-names></name><etal/></person-group><article-title>SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses</article-title><source>npj Vaccines</source><year>2021</year><volume>6</volume><fpage>151</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00414-4</pub-id><pub-id pub-id-type="pmid">34903722</pub-id><pub-id pub-id-type="pmcid">PMC8668928</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>SC</given-names></name><name name-style="western"><surname>Ricks</surname><given-names>KM</given-names></name><name name-style="western"><surname>Lakhal-Naouar</surname><given-names>I</given-names></name><name name-style="western"><surname>Jay</surname><given-names>A</given-names></name><name name-style="western"><surname>Subra</surname><given-names>C</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>JL</given-names></name><etal/></person-group><article-title>A SARS-CoV-2 spike ferritin nanoparticle vaccine is protective and promotes a strong immunological response in the cynomolgus macaque coronavirus disease 2019 (COVID-19) Model</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><fpage>717</fpage><pub-id pub-id-type="doi">10.3390/vaccines10050717</pub-id><pub-id pub-id-type="pmid">35632473</pub-id><pub-id pub-id-type="pmcid">PMC9145473</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halfmann</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Frey</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Loeffler</surname><given-names>K</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>M</given-names></name><name name-style="western"><surname>Maemura</surname><given-names>T</given-names></name><name name-style="western"><surname>Armbrust</surname><given-names>T</given-names></name><etal/></person-group><article-title>Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses</article-title><source>EBioMedicine</source><year>2022</year><volume>86</volume><fpage>104341</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104341</pub-id><pub-id pub-id-type="pmid">36375316</pub-id><pub-id pub-id-type="pmcid">PMC9651965</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>CL</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>JA</given-names></name><name name-style="western"><surname>Schaub</surname><given-names>JM</given-names></name><name name-style="western"><surname>DiVenere</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>HC</given-names></name><name name-style="western"><surname>Javanmardi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Structure-based design of prefusion-stabilized SARS-CoV-2 spikes</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1501</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1126/science.abd0826</pub-id><pub-id pub-id-type="pmid">32703906</pub-id><pub-id pub-id-type="pmcid">PMC7402631</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christensen</surname><given-names>D</given-names></name><name name-style="western"><surname>Polacek</surname><given-names>C</given-names></name><name name-style="western"><surname>Sheward</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>L</given-names></name><name name-style="western"><surname>McInerney</surname><given-names>G</given-names></name><name name-style="western"><surname>Murrell</surname><given-names>B</given-names></name><etal/></person-group><article-title>SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>941281</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.941281</pub-id><pub-id pub-id-type="pmid">36756130</pub-id><pub-id pub-id-type="pmcid">PMC9900178</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>T</given-names></name><name name-style="western"><surname>Israelow</surname><given-names>B</given-names></name><name name-style="western"><surname>Pe&#241;a-Hern&#225;ndez</surname><given-names>MA</given-names></name><name name-style="western"><surname>Suberi</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Luyten</surname><given-names>S</given-names></name><etal/></person-group><article-title>Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses</article-title><source>Science</source><year>2022</year><volume>378</volume><fpage>eabo2523</fpage><pub-id pub-id-type="doi">10.1126/science.abo2523</pub-id><pub-id pub-id-type="pmid">36302057</pub-id><pub-id pub-id-type="pmcid">PMC9798903</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zayou</surname><given-names>L</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>S</given-names></name><name name-style="western"><surname>Dhanushkodi</surname><given-names>NR</given-names></name><name name-style="western"><surname>Quadiri</surname><given-names>A</given-names></name><name name-style="western"><surname>Ibraim</surname><given-names>IC</given-names></name><name name-style="western"><surname>Singer</surname><given-names>M</given-names></name><etal/></person-group><article-title>A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident CD4+ and CD8+ memory T cells and protects against COVID-19-like symptoms and death caused by SARS-CoV-2 infection</article-title><source>J Virol</source><year>2023</year><volume>1</volume><fpage>e0109623</fpage><pub-id pub-id-type="doi">10.1128/jvi.01096-23</pub-id><pub-id pub-id-type="pmcid">PMC10734477</pub-id><pub-id pub-id-type="pmid">38038432</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Park</surname><given-names>HS</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Santos</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Luongo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters</article-title><source>PLoS Pathog</source><year>2023</year><volume>19</volume><fpage>e1011057</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1011057</pub-id><pub-id pub-id-type="pmid">37352333</pub-id><pub-id pub-id-type="pmcid">PMC10325082</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Nou&#235;n</surname><given-names>C</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>CE</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Park</surname><given-names>HS</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luongo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>4811</fpage><lpage>25.e4817</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.11.006</pub-id><pub-id pub-id-type="pmid">36423629</pub-id><pub-id pub-id-type="pmcid">PMC9684001</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elder</surname><given-names>E</given-names></name><name name-style="western"><surname>Bangalore Revanna</surname><given-names>C</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>C</given-names></name><name name-style="western"><surname>Wallin</surname><given-names>R</given-names></name><name name-style="western"><surname>Sj&#246;dahl</surname><given-names>J</given-names></name><name name-style="western"><surname>Winqvist</surname><given-names>O</given-names></name><name name-style="western"><surname>Mirazimi</surname><given-names>A</given-names></name></person-group><article-title>Protective immunity induced by an inhaled SARS-CoV-2 subunit vaccine</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>4743</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.06.015</pub-id><pub-id pub-id-type="pmid">37353452</pub-id><pub-id pub-id-type="pmcid">PMC10242152</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>IH</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>C</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sublingual dissolving microneedle (SLDMN)-based vaccine for inducing mucosal immunity against SARS-CoV-2</article-title><source>Adv Healthc Mater</source><year>2023</year><volume>12</volume><fpage>2300889</fpage><pub-id pub-id-type="doi">10.1002/adhm.202300889</pub-id><pub-id pub-id-type="pmid">37337388</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mudrick</surname><given-names>HE</given-names></name><name name-style="western"><surname>Massey</surname><given-names>S</given-names></name><name name-style="western"><surname>McGlinch</surname><given-names>EB</given-names></name><name name-style="western"><surname>Parrett</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Hemsath</surname><given-names>JR</given-names></name><name name-style="western"><surname>Barry</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Comparison of replicating and nonreplicating vaccines against SARS-CoV-2</article-title><source>Sci Adv</source><year>2022</year><volume>8</volume><fpage>eabm8563</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abm8563</pub-id><pub-id pub-id-type="pmid">36001674</pub-id><pub-id pub-id-type="pmcid">PMC9401629</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Killingley</surname><given-names>B</given-names></name><name name-style="western"><surname>Mann</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kalinova</surname><given-names>M</given-names></name><name name-style="western"><surname>Boyers</surname><given-names>A</given-names></name><name name-style="western"><surname>Goonawardane</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>1031</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01780-9</pub-id><pub-id pub-id-type="pmid">35361992</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><mixed-citation publication-type="other">Lindeboom RGH, Worlock KB, Dratva LM, Yoshida M, Scobie D, Wagstaffe HR, et al. Human SARS-CoV-2 challenge resolves local and systemic response dynamics. <italic toggle="yes">medRxiv</italic>, 2023.2004.2013.23288227 (2023).</mixed-citation></ref></ref-list></back></article></pmc-articleset>